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INTRODUCTION 
Acute pain in the post operative setting can have adverse physiological 
and psychological effects due to the stress hormone response induced by 
anaesthesia and surgery. Thus postoperative pain management plays a vital role 
in deciding the overall outcome of any surgery.  
Postoperative pain is of prime concern following abdominal surgeries. 
The main objective of  providing  postoperative analgesia is to make the patient 
comfortable without pain, promote early ambulation, improve respiratory 
function and early restoration of his/her routine life. In abdominal surgeries, 
incidence of postoperative pain is higher causing restriction of the 
diaphragmatic movements. This could result in basal atelectasis , respiratory 
tract infections due to decreased effort in coughing out the secretions, deep 
venous thrombosis due to poor ambulatory effort, all of which lead to increased 
duration of  hospital stay, expenditure, morbidity and mortality. 
Providing epidural block with local anaesthetic drugs in these patients, 
can efficiently relieve post operative pain. Regional analgesia for abdominal 
surgeries with epidural is commonly practised  nowadays.  
Bupivacaine is one of the commonly used drug for post operative 
analgesia. Bupivacaine belongs to aminoacyl group of local anaesthetics.  It has 
a Pka of about 8.1 with protein binding capacity of  95 % . It is highly potent,  
has a slow onset and  longer  duration of action.  O.25 % and lower 
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concentrations of Bupivacaine are preferred for use in obstetric patients and out 
patients for day care procedures. 
Fentanyl is 800 times more lipid soluble than Morphine and 
rapidly is absorbed from the epidural space and CSF. Its onset of action is very 
rapid which is about 15 – 30 minutes and its duration of action is 2-5 hours. The 
initial bolus dose of Fentanyl is 5 mcg/kg. Signs and symptoms of respiratory 
depression are very rare with this dose, although  case reports of respiratory 
depression at these doses are very rare. Pruritus is the most common side effect. 
Its complementary and synergistic anti-nociceptive interaction  results in 
analgesia with no respiratory depression, decreased incidence of tolerance, 
dependence and abuse. 
Neostigmine, an anticholinesterase drug, which is used to 
antagonize non-depolarizing muscle relaxants has been tried for post-operative 
analgesia as an off-label use. Being a quaternary amine, it does not cross blood-
brain-barrier . Epidural Neostigmine provides analgesia through M1 and M2 
receptors in the spinal cord, inhibiting the breakdown of acetylcholine. It also 
prolongs and intensifies the analgesia increasing cyclic guanidino-mono 
phosphate by generating nitric oxide. It prolongs motor block when combined 
with a local anesthetic. Neostigmine is supposed to prolong the action of 
Bupivacaine. 
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Autoradiographic studies have shown muscarinic binding in 
substantia gelatinosa and to a lesser extent in lamina II and lamina V of dorsal 
gray matter of spinalcord.  Neostigmine also displays peripheral and suprapinal 
analgesic activity, however the dose necessary to achieve this seems to be 
higher. However, intrathecal  Neostigmine also carries dose dependent nausea 
and vomiting. 
Several studies have demonstrated that the use of epidural 
Neostigmine is associated with lesser adverse effects and the proposed 
mechanism of analgesia is by drug spreading into Cerebrospinal Fluid (CSF) at 
the rate of 1/10th the epidural dose. 
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AIMS AND OBJECTIVES OF THE STUDY 
The aim of the study is to compare “The postoperative analgesic efficacy 
of epidural Bupivacaine, Bupivacaine plus Fentanyl  and Bupivacaine plus 
Neostigmine  in adults undergoing abdominal surgeries under general 
anesthesia”  by assessing : 
1. Duration of post operative analgesia, i.e, time interval between epidural 
drug bolus and time for first rescue analgesia. 
2. Ramsay sedation score. 
3. Postoperative nausea and vomiting. 
4. Pruritus . 
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ANATOMY AND PHYSIOLOGY OF PAIN  
PAIN PATHWAYS 
Pain is nothing but any noxious stimulus that is transmitted from the 
periphery to the cerebral cortex.  These noxious stimuli are primarily transmitted 
by the afferent neurons located in the dorsal root ganglia in the vertebral 
foramina at each spinal level. These afferent neurons have single axon which 
bifurcates to reach the peripheral tissues it innervates and other to the dorsal 
horn of the spinal cord. The majority of the first-order neurons send the 
proximal end of their axons into the spinal cord via dorsal (sensory) root 
ganglion  located at each spinal level. Once in the dorsal horn, in addition to 
synapsing with second order neurons, the axons of first-order neurons may 
synapse with interneurons ,  sympathetic neurons and ventral horn motor 
neurons. 
 The primary afferent neurons located in the dorsal horn of the spinal 
cord synpases with the second order neurons. The axons from these second 
order neurons cross the midline and ascend in the contralateral spinothalamic 
tract to reach the thalamus. Second order neurons in the thalamic nuclei synapse 
with the third order neurons, which in turn send projections through the internal 
capsule and corona radiata to the post central gyrus of the cerebral cortex.  
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Spinal cord gray matter was divided by Rexed into 10 Laminae. The 
first 6 Laminae, which make up the dorsal horn, receive all afferent neuronal 
activity, and represent the principal site of modulation of pain by ascending and 
descending neural pathways.  
Second-order neurons are of 2 types :  
1. Nociceptive specific neurons. 
2. Wide dynamic range neurons.   
Wide dynamic range neurons perceive both noxious and non – noxious stimuli. 
Nociceptive specific neurons are located  in lamina I of dorsal horn, and respond 
only to high threshold noxious stimulation. Wide dynamic range neurons are the 
most prevalent cell type in the dorsal horn. Although they are found throughout 
the dorsal horn, wide dynamic range neurons are most abundant in lamina . 
During repeated stimulation, wide dynamic range neurons characteristically 
increase their firing rate exponentially in a graded fashion ("wind-up") even 
with the same stimulus intensity. Most nociceptive C fibers send collaterals or 
terminate on  second order neurons in lamina I, II and to a lesser extent lamina 
V. In contrast, nociceptive Aδ fibers synapse mainly in lamina I,  
V and to a lesser degree lamina X. 
Lamina I responds primarily to noxious (nociceptive) stimulation 
from cutaneous and deep somatic tissues. Lamina II, also called the substantia 
gelatinosa, contains many interneurons and is believed to play a major role in 
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processing and modulating nociceptive input from cutaneous nociceptors. It is 
also of special interest because it is believed to be a major site of action for 
opioids. Visceral afferents terminate primarily in lamina V, and to a lesser 
extent in in lamina I. Lamina V responds to both noxious and non-noxious 
sensory input and receives both visceral and somatic pain afferent. Lamina VIII 
and IX make up the anterior (motor) horn. Lamina VII is also called the inter-
mediolateral column and contains the cell bodies of preganglionic sympathetic 
neurons.  
The axons of most second-order neurons cross the mid-line close 
their level of origin  i.e the anterior commissure to the contralateral of the spinal 
cord , before they form the spinothalamic tract and send their fibers to the 
thalamus, the reticular formation, the nucleus raphe magnus, and the 
periaqueductal gyrus. Other ascending pain pathways are also important e.g. 
spinoreticular, spinomesencephalic, spinohypothalamic, and spinotelencephalic 
tracts.  
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PHYSIOLOGY OF PAIN (NOCICEPTION): 
CENTRAL MODULATION OF PAIN: 
FACILITATION OF PAIN   :  
Neurochemical mediators of central sensitization include substance P , 
Vasoactive intestinal peptide, calcitonin gene-related peptide (CGRP), 
cholecystokinin (CCK) etc. But , the most important of these peptides are 
substance P and calcitonin gene-related peptide (CGRP), while glutamate is the 
most important excitatory amino acids. These substances interact with G protein 
couples receptors on neurons and causes changes in membrane excitability and 
thereby activating intracellular second messengers. Both these pathways cause 
an increase in intracellular calcium. The induction and maintenance of central 
modulation of pain is mainly mediated by these. 
 INHIBITION OF PAIN:  
The inhibitory neurotransmitters ( somatostatin, Acetylcholine, β- 
endorphin, norepinephrine, Gamma amino butyric acid ( GABA ) and glycine 
produce a hyperpolarization of the postsynaptic membrane called the inhibitory 
postsynaptic potential. They modulate nociceptive activity in the dorsal horn. 
Glycine and Gamma amino butyric acid ( GABA ) are the most common 
inhibitory neurotransmitters within the CNS. They play an important role in 
segmental inhibition of pain in the spinal cord.   
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SUPRASPINAL INHIBITION:  
Supraspinal and descending pathway fibres inhibit pain response in the 
dorsal horn. The endogenous opioids act presynaptically to hyperpolarize 
primary afferent neurons and inhibit the release of substance P. Whereas, 
exogenously supplied opioids have a totally different action. Their action is 
mostly exhibited postsynaptically, on the second order neurons in substantia 
gelatinosa of spinal cord. Both opioid and α2-adrenergic receptors have been 
described on or near the terminals of unmyelinated peripheral nerves. Excitatory 
and inhibitory muscarinic receptors exist on the postsynaptic cell.  
Muscarinic receptors are seen in abundance in the following areas :  
 Substantia gelatinosa of dorsal horn,  
 Motor neuron areas , and  
 Lamina 2 and lamina 3 areas of spinal cord have both M1 and  M2 
receptors. 
These are the areas , which  are responsible for anti- nociceptive effects. 
CLINICAL APPLICATION OF MUSCARINIC STIMULATION:  
Exogenously administered acetylcholine has a very short duration of 
action. This is due  to its rapid inactivation by acetylcholinesterase, at synaptic 
level. Long-acting anticholinesterases can cause prolonged stimulation of the 
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spinal muscarinic system . This has been proved to have a very high anti-
nociceptive property with no neurological side effects. Acetylcholinesterase 
inhibitors such as Neostigmine when administered intra-thecally,  acts by 
inhibiting endogenous breakdown  of acetylcholine.  Acetylcholine can cause 
analgesic affects by increasing production of nitric oxide in spinal cord.  This 
has been proven by observing higher levels of spinal cord nitrite following 
intrathecal administration of acetylcholine. 
Both muscarinic and nicotinic receptors take part in anti- nociception. 
It has also been found that the levels of acetylcholine and noradrenaline are 
increased in the spinal cord after administration of cholinomimetic substances. 
This mechanism has been proposed to be involved in producing cholinergic 
analgesia in acute nociception., such as post operative pain , whereas levels of 
nitric oxide are increased in spinal cord following chronic pain such as nerve 
injury.  
Antinociception by central muscarinic receptors is mainly 
dependent on M1 receptor subtype, whereas analgesia can be induced by 
stimulation of both postsynaptic M1 and presynaptic M2 muscarinic receptors in 
the brain. Analgesia can also be produced by inhibition of glutamate secretion in 
the presynaptic muscarinic receptors and activation of muscarinic receptors in 
the peripheral nerve endings.  
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Studies have shown  that  intrathecal (IT) Neostigmine provided 
analgesia in doses ≥ 10µg (surgical patients "as release of Ach is enhanced by 
pain") to ≥ 50 µg (volunteers).  
Whereas, Epidural Neostigmine acts on the enzymes 
acetylcholinesterase and butylcholinesterase expressed in the meninges that 
cover the spinal cord. Another aspect to be considered is the possible direct 
action of Neostigmine as a muscarinic agonist,in addition to the indirect 
stimulation of the release of the second intracellular messenger, nitric oxide. 
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EPIDURAL SPACE 
Is located between the duramater and the periosteum lining the vertebral canal. 
It extends from foramen magnum to the sacro-coccygeal ligament. Its contents 
include: 
1. Nerve roots, 
2. Fat , 
3. Areolar connective tissue, 
4. Lymphatics and , 
5. Blood vessels. 
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Epidural space also contains Batsons plexus. They are valve-less in 
nature. These plexuses communicate with pelvic veins through iliac veins and, 
abdominal and  thoracic venous systems through azygous veins. 
Epidural fat content is more in case of obese patients. Epidural fat also 
reduces as the age advances. Hence, reduction in drug dosage is required in 
elderly patients. 
PHARMACOKINETICS OF THE EPIDURAL ANAESTHESIA. 
Local anaesthetics when deposited into the epidural space acts by either,  
 Acts on the nerve in the intervertebral foramen, or 
 On the nerves in the subarachnoid space by diffusing into the space. 
LOCATING THE EPIDURAL SPACE : 
There are many techniques to identify epidural space like : 
1. Gutierrez sign or Hanging drop technique, 
2. Loss of resistance technique, 
3. Lund sign : Burning pain is felt by the patient when saline is injected into 
the epidural space, 
4. Bidigital pressure test, 
5. Free dripping saline technique, 
6. Queckenstedt test : compression of internal jugular vein causes pressure 
changes in epidural space. 
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However, the most common is loss of resistance technique. This 
technique was used in our study. 
PHARMACOLOGY:  
Choice of drug for producing: 
1. Surgical anaesthesia: it requires dense sensory blockade and  moderate to 
dense motor blockade. Hence, drugs are used in highest concentration. 
Like, 2% Lignocaine and 0.5 % Bupivacaine. 
2. Labour analgesia : 0.1% - 0.25% Bupivacaine is used, usually in range of 
5- 10ml. 
3. Post – operative analgesia : weaker concentrations of  0.1 % - 0.166 %.  
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PHARMACOLOGY 
BUPIVACAINE 
    
 
 
 
 
Bupivacaine belongs to the pipecoloxylidide group of local anaesthetics. 
These are chiral drugs because their molecules possess an asymmetric carbon 
atom.  As a result, Bupivacaine has a left and right handed configuration. Its  
white, odourless and  is soluble in water  and  95 % ethanol, and  less soluble in 
chloroform or acetone. 
ITS CHEMICAL STRUCTURE: 
 
 
Solution of Bupivacaine hydrochloride is clear and colorless.  It is used 
for local infiltrations, peripheral nerve blocks, epidural and caudal blocks. 
Bupivacaine hydrochloride injection solution can be autoclaved.   
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Bupivacaine belongs to aminoacyl group of local anaesthetics. It is a 
homologue of Mepivacaine and is chemically related to Lignocaine. All these 
three local anaesthetics  contain an amide linkage between the aromatic nucleus 
and the amino or piperidine group. These three differ in this respect from the 
procaine-type local anaesthetics, which have an ester linkage. 
Each ml of Bupivacaine hydrochloride injection contains  
 5 mg of  anhydrous Bupivacaine hydrochloride 
 8 mg of Sodium chloride 
 1 mg of Methylparaben. 
It is also available in 4ml ampoules where each ml contains  5mg  
hyperbaric Bupivacaine hydrochloride. 
BUPIVACAINE - CLINICAL PHARMACOLOGY: 
Bupivacaine acts by binding to the intracellular portion of voltage – gated 
sodium channels and blocks sodium influx into nerve cells, which prevents 
depolarization. 
It blocks the generation and the conduction of nerve impulses by: 
1. Increasing the threshold for electrical excitation in the nerve,  
2. Slowing the propagation of the nerve impulse, 
3. Reducing the rate of rise of the action potential.  
17 
 
Compared to other local anaesthetics, Bupivacaine is markedly 
cardiotoxic. At low / therapeutic doses ,Bupivacaine does not cause major 
cardiovascular changes or alters cardiac conduction or its contractility. 
However, toxic blood concentrations of Bupivacaine can cause  major 
abnormalities in cardiac conduction and excitability leading to major ventricular 
arrhythmias,  atrioventricular blocks and bradycardia. Depression of myocardial 
contractility  results in decreased cardiac output and arterial blood pressure , 
ultimately leading to cardiac arrest and death.  But, these changes have been 
found to be mostly due to inadvertent intravascular injection of Bupivacaine. 
However, its  racemic mixture ie S enantiomer is less cardiotoxic. 
Adverse effects on the central nervous system is mainly manifested as 
circumoral numbness, facial tingling, vertigo, tremors and convulsions.  
PHARMACOKINETICS: 
Like other local anaesthetics, the rate of absorption of Bupivacaine is 
mostly dependent on its route of administration, site of administration, total dose 
and concentration of the drug administered and the presence or absence of 
epinephrine in the anaesthetic solution. Epinephrine in concentrations of 
1:200000 in the anaesthetic solution prolongs the duration of action and permits 
usage of larger total doses by reducing the rate of absorption and peak plasma 
concentration of Bupivacaine.  
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Certain clinical studies have found that its highest peak plasma 
concentrations, maximum spread of analgesia and motor blockade is found in 
elderly patients compared to younger subjects.   
• The duration of anaesthesia : 240 – 480 minutes,  
( Bupivacaine like other liposomal local anaesthetics like lidocaine and 
tetracaine is incorporated into liposomes to prolong its duration of action and 
decrease its toxicity), 
• Half life: 210 minutes, 
• Maximum single dose for infiltration  : 175 mg, 
• Toxic plasma concentration :> 3 micro g / ml, 
• pka : 8.1 ( weak base ), 
• Plasma protein binding : 95% , 
• Fraction non- ionized  Bupivacaine at pH 7.4 is 17 % and  at pH 7.6 is 24%, 
• Volume of Distribution : 73 L, 
• Clearance : 0.47 L/ min . The total plasma clearance was decreased in elderly 
patients. 
The rate and degree of diffusion of any local anaesthetics  across the 
placenta depends on the following factors :  
(1)  plasma protein binding capacity of the drug,  
(2) the degree of its ionization  and  
(3) the lipid solubility of the drug.  
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The foetal to maternal circulation of local anaesthetics , is inversely 
related to its plasma protein binding capacity. Thus, only the unbound or free 
drug in the maternal circulation is available for placental transfer.  The plasma 
protein binding capacity of Bupivacaine is 95 %, hence, the ratio of umbilical 
vein to maternal arterial concentration of Bupivacaine is only 32%.   
Likewise, lipid soluble or water insoluble drugs which occur in 
nonionized form in the circulation readily crosses maternal circulation to enter 
the foetal  circulation, whereas water soluble or ionized drugs do not readily 
cross the pacental barrier. The lungs are also capable of extracting Bupivacaine 
from the circulation. 
Possible pathways for metabolism of  Bupivacaine include aromatic 
hydroxylation, N – dealkylation , amide hydrolysis and conjugation. Alpha- acid 
glycoprotein is the most important plasma protein binding site of Bupivacaine.  
The major metabolite of Bupivacaine is Pipecoloxylidide , which is mainly 
catalysed by cytochrome p450 3A4. Pipecoloxylidide is then hydroxylated to 
form glucuronide conjugates. 
The kidney is the main excretory organ for most local anesthetics and 
their metabolites. Urinary excretion is affected by urinary perfusion and factors 
affecting urinary pH. Only 6% of Bupivacaine is excreted unchanged in the 
urine. 
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FENTANYL 
     
 
 
 
ITS CHEMICAL STRUCTURE: 
Fentanyl citrate is chemically known as N-(1-phenethyl-4-piperidyl) 
propionanilide citrate . Each ml of its Injection contains 50 µg of Fentanyl 
citrate. It is a sterile, non-pyrogenic, preservative free aqueous solution for 
intravenous or intramuscular injection.  
The structural formula of Fentanyl citrate is  
 
 
 
FENTANYL : ITS CLINICAL PHARMACOLOGY: 
Fentanyl is a synthetic opioid belonging to the class of phenylpiperidines. It 
is a potent opioid agonist acting at mu receptor. Fentanyl has become a very 
popular anaesthetic agent because of these clinical properties:  
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 Its relatively short time to peak analgesic effect, 
 Its rapid termination of effect after small doses, 
 It is cardiac stable. 
Fentanyl is 100 times more potent than Morphine.  
The principal actions of  Fentanyl are analgesia and sedation. It produces 
its actions at a cellular level by activating opioid receptors. These opioid 
receptors are mainly located in thalamus, cerebral cortex,  substantia gelatinosa 
of spinal cord and peri – aqueductal grey area.  
Opioid receptors are coupled with inhibitory G-proteins. The activation 
of these inhibitory G-proteins results in: 
1. Closure of voltage sensitive channels, 
2. Decreased production cyclic adenosine monophospahte, 
3. And hyperpolarization ( due to stimulation of potassium efflux ). 
 All these effects causes reduction of neuronal cell excitability resulting 
in reduced transmission of nociceptive impulses. Pure opioid agonists like 
Fentanyl, Morphine, Pethidine and Diamorphine possess a  high intrinsic 
activity at this opioid receptor.  
When given intravenously, Fentanyl has a fast onset of action, but its 
peak analgesic action is reached within 5 minutes. Fentanyl being more lipid 
soluble than Moprhine, carries very low risk of respiratory depression from 
rostral spread of intraspinally administered narcotic to respiratory center. 
However, Fentanyl can cause alterations in alveolar ventilation and very high 
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decrease in pulmonary gas exchange, which can even last longer than its 
analgesic effect. This mostly occurs when Fentanyl is used in large doses or in 
prolonged infusions.  
Its peak respiratory depressant effect is mainly seen only after 5 to 15 
minutes after a single intravenous dose of Fentanyl citrate. Fentanyl can cause 
decrease in heart rate and mild decrease in blood pressure. However, it does not 
cause histamine release and is highly cardiac stable. This property, thus makes 
Fentanyl the primary anaesthetic agent for patients with poor cardiac function 
planned for cardiac surgery.   
PHARMACOKINETICS:  
• Volume of Distribution Fentanyl is  3-5 L/kg , 
• Duration of action : 30 to 60 minutes after iv injection, 
• Terminal Half life ( hours ) : 3.5 hours , 
• pKa : 8.4, 
• Amount of drug unionised Fentanyl at pH of 7.4:  9, 
• Amount of drug that is plasma bound:  84%, 
• Clearance (ml/min/kg): 0.8 – 1, 
• Relative Lipid solubility: 580 ( very high lipid solubility ). 
Fentanyl is primarily metabolised in the liver and  demonstrates a high 
first pass clearance.  75%  of the intravenous drug is excreted as metabolites in 
urine, with less than 10% representing the unchanged drug. Approximately 9% 
of the dose is recovered in the faeces, primarily as metabolites. 
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NEOSTIGMINE 
  
Neostigmine was introduced in 1931. Neostigmine consists of a 
carbamate moiety and a quaternary ammonium group. Carbamate moiety 
provides covalent bonding to acetylcholinesterase. Quaternary ammonium group 
renders the molecule lipid-insoluble, so that it cannot pass through the Blood 
Brain Barrier. 
ITS CHEMICAL STRUCTURE: 
 
   
 
MECHANISM OF ACTION:  
Neostigmine is an indirectly acting  cholinomimetic drug. It acts 
primarily by inhibiting the action of acetylcholinesterase, which hydrolyzes  
acetylcholine to choline and acetic acid. It combines reversibly with 
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Acetylcholinesterase by the formation of an ester linkage, which lasts about 30 
minutes. By inhibiting acetylcholinesterase, it increases the concentration of 
spinal endogenous acetylcholine. 
Muscarinic receptors are located in cholinergic interneurons of the dorsal 
horn of the spinal cord, in the substantia gelatinosa, in laminae III and V of the 
spinal cord; while α3, α4, α5, α7, β2, β3 and β4 nicotinic subunits are expressed 
on primary afferent terminals, inhibitory interneurons, descending noradrenergic 
fibers in the dorsal root ganglion and in microglias. 
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It was demonstrated that activation of spinal muscarinic type-2 receptors 
suppressed spinal gamma-amino butyric acid-B (GABA-B) receptor input and 
that this dis-inhibiting mechanism ultimately lead to the release of adrenal 
catecholamines and subsequent reduction in peripheral inflammation. Spinal 
cord stimulation was also associated with the activation of the cholinergic 
system in the dorsal horn and mediated via muscarinic receptors, particularly 
M4, while nicotinic receptors appeared not to be involved. In addition spinal 
Neostigmine administration resulted in reduction in levels of  substance P, and 
there appears to be unidirectional cross-tolerance between morphine and 
Neostigmine. In cats, spinal Neostigmine showed antinociceptive effect and this 
inhibition was only partially mediated by cholinergic mechanism. 
Epidural Neostigmine analgesia seems to be a result of central rather than 
peripheral action. In patients undergoing surgery, epidural Neostigmine resulted 
in analgesia after the administration of a ten-fold lower dose (1 μg/kg), when 
compared to intraarticular administration in the knee, suggesting a central effect. 
Epidural Neostigmine acts on the enzymes acetylcholinesterase and 
butylcholinesterase expressed in the meninges that cover the spinal cord.  
PHARMACOKINETICS:  
The pharmacokinetics of Neostigmine administered by bolus 
injection is linear with respect to bolus injection. The time of the peak 
concentration ranged from 5-30 minutes. The absorption phase is followed by a 
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bi- exponential distribution and elimination phase. Diffusion in CSF plays a 
major role in drug distribution. There is a sustained plateau of increased 
Acetylcholine  concentration in CSF after intrathecal  Neostigmine 
administration. It has been found that CSF Neostigmine concentration even in 
the lowest of doses can significantly inhibit cholinesterase in CSF.  
Dosage of intrathecal administration:  
From controlled clinical studies it has been found that the effective dose 
of intrathecal Neostigmine to produce good analgesic effect is about 10-100 µg. 
Side effects:  
Neostigmine when given intrathecally can cause lower limb weakness 
and hypertension due to its local spinal cord action. It also produces sedation 
and gastrointestinal side effects, which are mainly due to its central action. The 
incidence and severity of these adverse effects mainly depends on : 
 the dose of Neostigmine used, 
  method and route of administration and, 
  the baricity of the solution.  
The incidence of nausea and vomiting is about 30% following intrathecal 
administration of Neostigmine. Small dose of about 6.25µg  of intrathecal 
Neostigmine can cause nausea and vomiting which is severe , prolonged and 
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quite resistant to anti –emetic and prokinetic drugs. Nausea and vomiting is 
reduced by injecting it in a hyperbaric solution. Currently available formulations 
contain the preservatives methyl  and propyl–paraben and are usually mixed 
with glucose to yield hyperbaric solutions.  
Administration of Neostigmine by the epidural route would be mainly 
characterized by the action of enzymes located in the meninges, with low 
participation at spinal sites. Gastrointestinal symptoms like nausea and vomiting 
are rare with epidurally administered Neostigmine. Until date, epidural doses 
exceeding 30 μg/kg were associated with a higher incidence of nausea and 
vomiting and post-operative sedation was increased after 300 μg epidural 
Neostigmine following caesarean delivery. 
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REVIEW OF LITERATURE 
 
In one prospective randomized double-blind study evaluating  low-dose 
Dexmedetomidine and Neostigmine with Bupivacaine for postoperative 
analgesia in orthopedic surgeries done by Sharma. A et al. (1) showed that 
epidurally administered Dexmedetomidine and Neostigmine exhibit synergism 
in analgesic action. The incidence of drug-related side-effects was also low.  In 
their study  60 patients belonging  to ASA class 1 and 2 who required lower 
limb surgeries of ≤3 hours duration where subjected to combined spinal - 
epidural anaesthesia. The patients were randomized into three groups. The 
epidural drug was administered at the end of surgery ,with the patients in Group 
I, II and III receiving  6 ml of 0.25% Bupivacaine alone, with 1 ug/kg of 
Neostigmine and with 0.5 ug/kg of Dexmedetomidine + 5 ug/kg of 
Neostigmine, respectively. Post op rescue analgesia was given with intravenous 
Tramadol 50 mg. The patients were assessed for hemodynamic changes, visual 
analogue pain scores, duration of analgesia, rescue analgesic requirements and 
the incidence of side-effects over the next 10 hours. Data was analyzed and P < 
0.05 was considered as statistically significant. The study revealed that the 
patients in Group III had significantly longer mean duration of analgesia (273.5 
min) compared to Group II (176.25 min) and Group I (144 min). There was also  
increased requirement of fluids to maintain blood pressures in Group III. 
Neostigmine did not cause any significant gastrointestinal side effects. 
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In a randomized, double-blinded study, conducted by Mohamed 
Abdulatif et al (2) to examine the post operative analgesic efficacy of caudal 
Neostigmine, Bupivacaine, or Bupivacaine with Neostigmine  in 60 children 
undergoing  hypospadias surgery  revealed that the patients receiving 
Bupivacaine  or a Bupivacaine and Neostigmine mixture required less inhalation 
anesthetics. The children in the Bupivacaine/ Neostigmine group also 
experienced better analgesia. These children also had  prolonged duration of 
analgesia.  
Roelants et al. (3) studied the use of the use of neuraxial adjuvant drugs 
like Neostigmine and Clonidine for labour  analgesia in obstetric patient. They 
found that small doses of intrathecal Clonidine (30 μg), combined with local 
anaesthetics and opioids, prolong labour analgesia. Hypotension is a common 
problem  and must be promptly treated with Ephedrine to avoid fetal side 
effects, but epidural Clonidine in doses of 60 to 75μg  produces prolonged 
analgesia when combined with local anaesthetics . Intrathecal Neostigmine has 
analgesic properties, but its gastro-intestinal side effects contraindicate its 
clinical use. Epidural Neostigmine, combined with Sufentanil or Clonidine, 
initiates labour analgesia when used in doses of minimum 6 to 7 μg/kg or 500 
μg without any such side effects, and allows for a walking epidural. 
Kumar. P et al. (4) did a study in paediatric patients posted for inguinal 
herniotomy. They used Midazolam, Ketamine, and Neostigmine  were used as 
additives to caudal Bupivacaine. They found out there was no significant 
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hemodynamic changes in neither of the 3 groups. The duration of post operative 
analgesia was significantly higher in Group Bupivacaine + Neostigmine ,Group 
Bupivacaine + Midazolam and Group Bupivacaine + Ketamine , compared with 
Group Bupivacaine . (P < 0.05). Group Bupivacaine + Neostigmine  and  Group 
Bupivacaine + Midazolam  a longer time to first rescue analgesia when 
compared with Group Bupivacaine + Ketamine.The incidence of vomiting was 
not significantly different among groups. However, two patients in Group 
Bupivacine +Ketamine experienced hallucinations. 
Another study by Kaya FN et al. (5)  in patients posted for caesarean also 
confirmed that epidural Neostigmine did increase the duration of post operative 
analgesia. In their study , the randomly selected eighty patients underwent 
elective caesarean section under combined spinal –epidural anaesthesia. These 
patients were divided into 2 groups. Both the groups received 8 mg hyperbaric 
Bupivacaine plus 10 μg Fentanyl intrathecally , but the Neostigmine Group 
received 300 μg Neostigmine ( n= 40 per group )  in 10 ml saline after clamping 
of the umbilical cord, whereas the Saline Group received only saline. Post op 
pain relief was monitored using visual analogue score and sedation using 
Ramsay sedation score for the first 24 hours. The study found that the global 
pain satisfaction was significantly reduced in the Neostigmine group. They also 
found that the Neostigmine group also experienced dose dependant increase in 
sedation scores (P < 0.05).  
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A comparative study was done by Fyneface-Ogan S et al.(7) between 
caudal Bupivacaine and Bupivacaine co-administered with Neostigmine for 
postoperative analgesia in children in which 66 children aged between 1-6 years, 
of ASA class  I or II posted for elective unilateral herniotomy under general 
anaesthesia without premedication were studied. The Mean duration of post 
operative analgesia in patients who received mixture of  Bupivacaine with 
Neostigmine was significantly longer, 460 ± 60.2 min. compared to the group 
which received only plain Bupivacaine, 286.4 ± 47.8 mins, (p < 0.001). The 
analgesic requirement within the first 24 hours postoperatively was also 
significantly reduced in that group, p < 0.001. 
A comparative study on the post operative analgesic efficacy of  
Neostigmine and Fentanyl as adjuvants to Bupivacaine  was done by Tekin S et 
al. (9) in patients undergoing abdominal hysterectomy  under general 
anaesthesia. The study was conducted in Seventy-five adult females between the 
age group 18- 65 years belonging to the American Society of Anesthesiologists 
physical status I-II. These patients were subjected to epidural insertion before  
undergoing surgery under general anaesthesia. After completion of the surgery , 
these patients were randomly chosen and divided into 3 groups. The patients in 
Group B received 0.125% Bupivacaine, Group N received  0.125% Bupivacaine 
plus Neostigmine 4 ug/ kg and Group F with 0.125% Bupivacaine plus 1 ug/ kg 
Fentanyl solutions . They found that the total analgesic consumption in Group F 
and Group N was considerably lesser when compared to the patients in Group 
B(p<0.05).  
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And  in one study, Chia YY et al (12) evaluated the efficacy of thoracic 
epidural infusion of  Neostigmine after thoracotomy. In this study, ninety 
patients were randomized into 3 groups i.e pre – neo , post – neo and control 
group . All these patients were subjected to epidural catheterization at T5 – T8 
levels. They underwent thoracotomy under general anaesthesia. The patients in 
pre-neo group were given 500 µg  Neostigmine epidurally before induction of 
anaesthesia and 125 µg / hour through epidural infusion till the completion of 
the surgical procedure. The patients in Post-neo group were given only saline 
epidurally before anaesthesia induction , but 500 µg epidural Neostigmine bolus 
at the end of the surgery. While the patients in the control group were given only 
saline as placebo. The patients in the pre – neo and post – neo groups were 
subjected to receive a mixture of Morphine , Neostigmine and Bupivacaine 
through continous patient controlled epidural analgesia in the post operative 
period for the next 6 days. The patients in the control group received only 
mixture of Morphine and Bupivacaine  through continous patient controlled 
epidural infusion. These patients were followed up for the next 6 days. From the 
study they found out that the daily requirement of  patient-controlled epidural 
analgesia in mL for the patients in the Pre-neo group was remarkably less when 
compared to the requirement levels of patients in  post-neo and control groups. 
(P < 0.05).  They also found that the intensity and severity of pain was also 
considerably low in patients of pre- neo group, particularly in the first 3 days.  
(P < 0.05).  
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Lauretti GR et al. (14) studied the postoperative analgesic property of  
intra-articular and epidural Neostigmine in 58 ASA physical status I and II 
patients undergoing knee surgery  under combined Spinal – epidural  
anaesthesia. All the patients in the study were subjected to epidural 
catheterization at L2-3 space and spinal blockade was performed at L3-4 space. 
The dose of spinal anaesthesia in all these patients was 20mg of hyperbaric 
Bupivacaine. After this , the patients were randomly divided into three groups. 
The Group EG received 500µg epidural Neostigmine and intra- articular saline, 
the patients in group AG received epidural saline and 500 µg intra- articular 
Neostigmine , whereas the patients in group CG received saline both epidurally 
and intra- articularly. Dose of 10 ml was selected for both epidural and intra-
articular injection. The study revealed that duration of post operative analgesia 
was significantly higher in the patients in Groups EG and AG when compared to 
the patients in Group CG (P < 0.05). The total analgesic consumption was also 
significantly higher in the control group CG (P < 0.05).They also found that 
when the dose of Neostigmine was only 1 µg / kg, the post operative analgesia 
when given intra – articularly was of not much significant. However, when the 
similar 1 µg /kg dose of Neostigmine was given epidurally , it provided 
significant post operative analgesia for about 5 hours.  
In one study Ross VH et al. (16) did a randomized controlled study on a 
group of obstetric patients using Bupivacaine and Neostigmine as  patient 
controlled epidural analgesia in 40 healthy patients posted for elective caesarean 
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section. In these patients  Bupivacaine 1.25 mg/mL alone or with Neostigmine 4 
ug /mL by patient-controlled epidural analgesia. The primary outcome measured 
by them was hourly Bupivacaine use. The result of this study proved that 
Epidural Neostigmine bolus did not alter baseline Foetal heart rate, induce 
uterine contractions, or produced gastro-intestinal side effects.. Epidural 
Neostigmine infusion reduced Bupivacaine requirement by 19% in all patients 
and 25% in those with >4 h of treatment (P < 0.05 for both). It was also found 
that these patients also experienced mild sedation. 
 Zhang N et al. (18)  did a study using epidural Clonidine and 
Neostigmine, and their effects when used for labour analgesia. The patients 
were randomly selected into two groups by double blinding technique. They 
found out that when Epidural Clonidine and Neostigmine were used adjuvants 
to epidural Bupivacaine for labour analgesia , there was a significant analgesic 
effect ( monitored through vas scores ) (P < 0.05 ). There was also a significant 
reduction in the dose of Bupivacaine and opioids used for rescue analgesia.  
(P < 0.05 ).  
In a study by Heba I.A. et al. (20) where the effect of addition of 
Neostigmine to epidural Levobupivacaine/Fentanyl mixture on return of 
intestinal motility in cases posted for abdominal hysterectomy.  There were a 
total of 40 patients who were divided into group N (Neostigmine group) and 
group C (control group). In group N, Neostigmine 1 μg/kg was added to the 
epidural infusion of Levobupivacaine and Fentanyl. They found that Group N 
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had significantly lower visual analogue scale (P < 0.05). In addition, time to first 
analgesic request was significantly longer in group N (9.5+ or −1.3 vs. 8.1+  
or −0.9 in group C). The number of patients requiring analgesia in group N was 
two (10%), whereas in group C the number was nine (45%), which was 
statistically significant. Total narcotic consumption was significantly less in 
group N (104 ± 21.6 vs. 218 ± 35.2 mg in group C) and return of intestinal 
sounds was significantly faster in group N (8.1 ± 0.7 vs. 10.5 ± 1.8 h in group 
C). Group N had less nausea and vomiting.  
In November 2014 Mohamed AmrAbusabaa et al. (22) evaluated the 
efficacy of epidural Dexmedetomidine, Tramadol, or Neostigmine for  
postoperative pain after major breast surgeries. In this study Eighty female 
patients scheduled for major breast surgery were divided into four equal groups 
(20 patients each) in a randomized double-blinded manner. Thoracic epidural 
anesthesia was given at T6-7 level and the surgery was carried out under general 
anaesthesia. In group C 15 ml of 0.5% Bupivacaine (control group), in group D 
15 ml of 0.5% Bupivacaine +75 μg of Dexmedetomidine, in group T 15 ml of 
0.5% Bupivacaine +75 mg of Tramadol, and in group N 15 ml of 0.5% 
Bupivacaine +75 μg of Neostigmine were given. Perioperative cortisol levels, 
postoperative analgesia, time to ambulation, and complications were assessed as 
the major outcome following surgery. Patients in groups D and T experienced 
lower pain scores compared with patients in groups C and N . Hence, patients in 
groups D and T consumed a lower dose of Bupivacaine in the postoperative 
period compared with patients in groups C and N.  
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Gabriela Rocha Lauretti et al. (24)  in 2014, did a double-blinded  
prospective study in 60 boys of ASA physical status I or II undergoing  
unilateral orchidopexy under general anaesthesia combined with caudal block. 
They compared the efficacy of  intravenous and caudal routes of Sufentanyl and 
addition of caudal Adrenaline and Neostigmine as an adjuvant to Sufentanyl in 
children undergoing  unilateral orchidopexy under general anaesthesia combined 
with caudal block. Sixty patients scheduled for orchidopexy were divided into 
the following four groups: 1) Group IVSu received IV 0.5 μg/kg Sufentanyl and 
caudal saline; 2) Group CSu received caudal 0.5 μg/kg Sufentanyl and IV saline; 
3) Group CSuAdr received caudal Sufentanyl plus Adrenaline 5 μg/ml 
(1:200,000) and IV saline; 4) Group CSuNeo received caudal Sufentanyl plus 
Neostigmine, and IV saline; and 5) Group CSuNeoAdr received caudal 
Sufentanyl plus Neostigmine plus Adrenaline, and IV saline. Consumption of 
Isoflurane, side effects, quality of sleep, time to first administration of rescue 
analgesia, and number of doses of 24-h rescue analgesia were recorded. Heart 
rate and mean blood pressure >15% was treated with increasing  Isoflurane 
concentration. They found out that the total Isoflurane consumption was higher 
and similar in Groups  IVSu, CSuNeo and CSuNeoAdr, and lesser in  Groups  
CSu and CSuAdr (P < 0.02). Visual Analogue score  for sedation on reversal of 
anesthesia revealed  that the sedation scores in Groups  CSuNeo and 
CSuNeoAdr  was less when compared to Groups CSu, CSuAdr and IVSu (P < 
0.005). The time to the first administration of rescue analgesia  showed that the 
groups IVSu, CSu and CSuAdr required rescue analgesia very early in the post 
operative period which was around (3-4 h) , and that was significantly higher in 
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Groups CSuNeo and CSuNeoAdr (10-11 h) (P < 0.05). Number of doses of 
rescue analgesia showed the following association like  GroupIVSu = Group 
CSu = Group CSuAdr> Group CSuNeo = Group CSuNeoAdr (P< 0.005). They 
concluded  that  caudal Sufentanyl alone was no  better  when administered in 
the IV route, and would just be justified by the association of Neostigmine, but 
not Adrenaline. Neostigmine as an adjuvant to Sufentanyl  resulted in better 
perioperative analgesia. 
In 2012 , Amit Jain et al. (26) did a study in patients posted for total knee 
replacement surgery. They “ compared the post operative analgesic efficacy of 
low dose intra- thecal Neostigmine as an adjuvant to Fentanyl and Bupivacaine 
for total knee replacement surgery” . In this study forty-five patients were 
selected  and divided into three groups. All patients received intrathecal 
Bupivacaine 15 mg with group 1 patients receiving  Bupivacaine with normal 
saline (0.1 ml), group 2 patients receiving intrathecal Bupivacaine with Fentanyl 
20 ug (0.4 ml) and group 3 patients receiving intrathecal  Bupivacaine  with 
Neostigmine 1 ug (0.1 ml). From this study, they concluded that the analgesia 
produced by the Fentanyl group was better when compared to the Group which 
received intra-thecal Neostigmine. (P < 0.05 ). However,  the total duration of  
post op analgesia was significantly high in group 2 and group 3. . (P < 0.001 ). 
The total number of rescue analgesia required was significantly higher in group 
1(P < 0.05 ). They also found that epidural Neostigmine did not cause any 
adverse gastrointestinal side effects like nausea and vomiting. 
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Medge D. Owen et al. (27) in 2000 did a study using  “Low-dose 
Clonidine and Neostigmine as an adjuvant to local anaesthetics and observed 
that they can prolong the duration of labour analgesia when combined with 
spinal hyperbaric Bupivacaine and Fentanyl”.  In their study, 45 healthy patients 
in active stage of labour were divided into 3 groups. All these patients were 
subjected to combined spinal- epidural technique. Each patient in group 1 
received 2.5 mg of hyperbaric Bupivacaine  and 25 μg  Fentanyl. The patients in 
group 2 received a mixture of hyperbaric Bupivacaine 2.5 mg , Fentanyl 25 μg  
and Clonidine 30 μg , whereas the patients in group 3 received a mixture of 2.5 
mg hyperbaric Bupivacaine , Fentanyl 25 μg , Clonidine 30 μg  and 
Neostigmine 100 μg . The total intra-thecal dose was 2ml in all the 3 groups. 
They found that the total duration of labour analgesia was very high in group 3 
where mixture of Bupivacaine, Fentanyl, Clonidine  and Neostigmine was used . 
They also found out that this group also had a very high incidence of 
gastrointestinal side effects like nausea and vomiting.  
 In one study conducted by Cossu AP et al. (29), Neostigmine was used 
as an adjuvant to local anaesthetics for neuraxial blockade in obstetric patients 
to find out its efficacy in producing post operative analgesia.  From this study , 
they found that the epidural addition of Neostigmine to local anaesthetic like 
Bupivacaine or Ropivacaine resulted in greater analgesic response and greater 
patient tolerance when compared to the intra-thecal administration of 
Neostigmine. Post op requirement of subsequent doses of local anaesthetics was 
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also significantly reduced. (P < 0.05 ). Intra-thecal administration of 
Neostigmine was associated with vomiting in nearly half of the patients, but not 
with the patients who received epidural Neostigmine. They also found that 
epidural Neostigmine administration can cause mild to moderate sedation.  
In 2012 ,Hany A. Shehab and Samar A. Salman (32)  conducted a study 
in 90 women belonging to ASA class 1 and 2 who were subjected to undergo 
open abdominal hysterectomy for dysfunctional uterine bleeding  under epidural 
combined with general anaesthesia. The purpose of the study was to compare 
the therapeutic efficacy of a preoperative epidural single shot  of 
Dexamethasone/ Levobupivacaine and Neostigmine/ Levobupivacaine for 
postoperative analgesia. The patients were randomly divided into three equal 
groups on the basis of the use of epidural adjuvant as only one preemptive shot 
epidural injection: group L included patients assigned to receive 12 ml of plain 
Levobupivacaine 0.1% (1 mg/ml), group L/D included patients assigned to 
receive a total volume of12 ml of both Levobupivacaine 0.1% (1 mg/ml) and 
Dexamethasone 8 mg, and group L/N included patients assigned to receive a 
total volume of 12 ml of both Levobupivacaine 0.1% (1 mg/ml) and 
neostigmine 500 ug. They found out that the preemptive epidural therapy 
provided PO analgesia without significant difference until 2 hours 
postoperatively. Until 8 hours postoperatively, pain VAS scores were 
significantly lower in groups L/D and L/N compared with group L; at 10 hours  
postoperatively, pain VAS scores were significantly lower in the L/D group 
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compared with the other groups. The total pain VAS score at the end of 24 h 
was significantly lower in the L/D group compared with the L/N and L groups, 
with significantly lower scores in the L/N group compared with group L. The 
mean duration of PO analgesia was significantly longer in the L/D group 
compared with groups L/N and L, with significantly longer duration in the L/N 
group compared with group L. 
In one other study by Rajesh Mahajan et al. (35), different doses of  
caudal Neostigmine in was used as an adjuvant to Bupivacaine  to analyse its 
analgesic property in children undergoing repair of hyposapdias. These children 
were randomly allocated into 4 groups. The children in group 1 received  caudal 
Bupivacaine with saline being the control group. The children in group 2 
received caudal Bupivacaine with caudal Neostigmine in doses of 2 µg/kg , 
group 3 with caudal Bupivacaine and 3 µg/kg  caudal Neostigmine and children 
in group 4 received caudal Bupivacaine with 4 µg/kg caudal Neostigmine. From 
the study , they inferred that the duration of post operative analgesia was 
considerably higher in groups 2, 3 and 4 when compared to the group 1. Among 
the three caudal Neostigmine groups, the 4 µg/kg  caudal Neostigmine group 
showed a significant  increase in duration of post op analgesia whrn compared 
to the 2 µg/kg   and 3 µg/kg  caudal Neostigmine group. In this study 
intravenous Paracetamol was used as the rescue analgesic in all the 4 groups. 
From this they conclude that the amount of rescue analgesia consumption  
(in ml) was also significantly higher in the group 1 compared to the groups 2, 3 
and 4. 
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In 2012, SayedKaoudAbd-Elshafy et al. (36) did a study using 
Neostigmine as an adjuvant to Bupivacaine in caudal block for children 
undergoing open heart surgery under general anaesthesia. These children  
randomly allocated into 2 groups in a double blinded manner. After performing 
orotracheal intubation in these children, the patients  in group 1 received a 
caudal block using Bupivacaine and 2 µg/kg  dose of caudal Neostigmine. 
Whereas, the children in group 2 were given intravenous Fentanyl  infusion 
throughout the post operative period. From this study, they concluded that 
weaning from mechanical ventilation in the post op period was early in the 
children  in group 1 than group 2. The children in group 1 also experienced 
longer post op duration of  analgesia. Thus, they concluded that caudal 
Neostigmine as an adjuvant to Bupivacaine  facilitated early extubation and 
provided longer duration of postoperative analgesia in children undergoing open 
heart surgery under general anaesthesia. 
MamtaHarjai et al (37) in 2010  did a randomized double blind study on 
ninety adult females who underwent lower intra abdominal surgeries comparing  
two different doses of epidural Neostigmine administered with Lignocaine for 
post operative analgesia and sedation. They divided the patients into three 
groups of 30 each. Group I received Lignocaine 1% (9ml) with normal saline 
(1ml), group II Lignocaine1% (9ml) with Neostigmine 100μg in saline (1ml) 
and group III received Lignocaine 1% (9ml) with Neostigmine 200μg in NS 
(1ml).After putting epidural catheter, all these patients underwent surgery under 
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general anesthesia using  Propofol (2mg kg-1), Succinylcholine (2mg kg-1) and 
maintained with O2, N2O, relaxant technique. At the end of surgery, patients 
were reversed and extubated. Epidural analgesic medication was administered to 
after proper recovery from anesthesia. Intensity of pain relief on VAS, duration 
of analgesia, level of sensory block, motor blockade, sedation by sedation score 
and complications were assessed. From these findings they found out that the 
addition of Neostigmine resulted in significant longer duration of analgesia 
(dose independent) and sedation (dose dependent). Sensory and motor blockade 
were identical in all three groups. There was no incidence of respiratory 
depression, pruritus, bradycardia or hypotension in any group. 
One other study on the analgesic efficacy of epidural Neostigmine as an 
addictive to Bupivacaine was done by Nakayama. M et al. (40). Forty five ASA 
1 patients posted for elective abdominal hysterectomy were enrolled in this 
study.  These patients were randomly divided into 3 groups. All these patients 
were subjected to epidural catheterization at T12- L1 space in the pre op period 
and underwent abdominal hysterectomy under general anaesthesia. At the end of 
the surgery, the patients in group 1 were given epidural Bupivacaine  alone with 
saline , the patients in group 2 with epidural Bupivacaine mixed with 
Neostigmine in dose of  5 μg,/kg and the patients in group 3 received epidural 
Bupivacaine mixed with Neostigmine in dose of 10 μg,/kg. They found that the 
time to first rescue analgesia was longer in the 5 μg,/kg and 10 μg,/kg 
Neostigmine groups.   
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A  study on labour analgesia using mixture of epidural Clonidine and 
Neostigmine  with Ropivacaine  was done by Boogmans et al, (41). In this study 
, parturients in their active stage of labour were subjected to labour analgesia by 
combined spinal epidural technique.  From this study , they found out that the 
group of patients who were subjected to undergo labour analgesia using the 
mixture of epidural Neostigmine and Clonidine to spinal Ropivacaine showed 
that the total use of local anaesthetics i.e Ropivacaine used in this group was 
very less. (P <0.05) The quality of analgesia and the duration of analgesia was 
also higher in this group.  
Getu Ataro et al. (43) did a comparative study between caudal 
Neostigmine added to Bupivacaine  and caudal Bupivacaine alone on paediatric 
patients undergoing elective orthopaedic surgery under general anaesthesia.  The 
children who are posted for elective orthopaedic surgery of the lower limbs were 
randomized into 2 groups. The children in group 1 received only caudal 
Bupivacaine( 0.125%)  , whereas the children in group 2 received caudal 
Bupivacaine ( 0.125%) with Neostigmine in dose of 2 μg,/kg at the end of the 
procedure . They concluded that the duration of analgesia and time to first 
rescue analgesia was longer in group 2. The values were also highly significant 
(p <0.003).  
Mayank Mohan Agarwal et al. (44) did a study in adult patients of 40 – 
60 years of age. These patients were devoid of any urinary tract infections or 
voiding problems.  The purpose of this study was to monitor the urinary tract 
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function in these adult patients after epidural administration of Neostigmine. 
After insertion of an epidural catheter at lumbar levels , these patients 
underwent rigid cystoscopy under local anaesthesia. They underwent 
multichannel urodynamics (filling cystometry and pressure-flow study) before 
and 30 min after lumbar epidural administration  of  Neostigmine (2 µg/kg). 
They found that these patients had very low maximum cystometric capacity 
with no alterations in end filling pressure.  These patients also experienced very 
good analgesic effects in the post operative period. 
Yet an another study to evaluate the effects of  epidural Neostigmine on 
post operative ileus in patients posted for elective abdominal aortic aneurysm 
surgery was conducted by Caliskan et al (46) in 2003. The patients posted for 
abdominal aortic surgery were allocated into 2 groups. Thoracic epidural 
catheter was inserted pre -operatively in all these patients. These patients were 
allowed to undergo abdominal aortic aneurysm under general anaesthesia. At 
the end of the surgery , the patients in the group 1 received a 5-mL bolus of 
Neostigmine in dose of 1 μg/kg  diluted with normal saline , whereas the 
patients in Group 2 received  only 5 mL normal saline. The patients in both the 
groups received 0.125% Bupivacaine continuously via epidural infusion pumps 
for the next 48 hours. They observed that the patients in group 1 experienced 
early return of bowel activity , compared to the patients in group 2.  These 
patients also passed flatus early in the post operative period. (P < 0.05).  
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Eiji Masaki et al. (48) studied the postoperative analgesic effects of 
epidural Neostigmine and the responses of plasma cortisol and Interleukin-6.  
The study was done in 20 patients undergoing lower abdominal surgery. The 20 
patients were allocated into 2 groups. Neostigmine group (n=10) received 
epidural 10 ml of 1% Mepivacaine with 0.1 mg Neostigmine before the 
induction of general anaesthesia, while control group (n=10) received 
Mepivacaine alone. The general anaesthesia was induced with Propofol (2 
mg/kg) and Vecuronium (0.1 mg/kg), and maintained with Sevoflurane / O2 / 
N2O. Blood was collected at various time intervals , before and after induction 
of anaesthesia and in the post operative period  to assess the effects of 
Neostigmine on the plasma cortisol and interleukin-6 levels.  From this study , 
they concluded that patients who received epidural Neostigmine before skin 
incision showed low cortisol levels even in the intra – operative period , whereas 
the patients in the control group showed high cortisol levels. (P  < 0.05).  There 
was no change in the interleukin – 6 levels in both the group of patients.  
(P > 0.05). 
Alparslan Turan et al. (52) evaluated the effect of caudal Ropivacaine 
and Neostigmine in paediatric patients posted for elective surgery of inguinal 
hernia or hypospadias. They divided them into Group I (n = 22), who received 
0.2% Ropivacaine 0.5 ml/kg, and Group II (n = 22), who received 0.2% 
Ropivacaine 0.5 ml/kg with 2 μg/kg Neostigmine via the caudal route. From this 
study they found that the patients in group 2 showed very low VAS scores  
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when compared the patients in group 1. The values were also highly significant. 
(P < 0.001).  But, the post operative sedation scores in both the group of patients  
were similar and not significant.  
In 2003,  Y.K. Batra et al. (58) did a study in 120 ASA class 1 children 
posted for elective hypospadias correction surgery . They used Neostigmine as 
adjuvant to Bupivacaine to find the its afficacy in providing post op analgesia in 
these children. Adequate dose of caudal Neostigmine when added to caudal 
Bupivacaine did increase the duration of analgesia in these patients. However, 
they found that higher doses of Neostigmine caused vomiting in some patients.  
I. Saadawy at al. (63) in 2008 did a study to evaluate the effects of 
Dexmedetomidine on paediatric patients when used as an addictive  to 
Bupivacaine in caudal block. The children included in the study were allocated 
into 2 groups. They found that the end-tidal Sevoflurane concentration and the 
incidence of agitation were significantly lower in the Group where 
Dexmedetomidine was used as additive to caudal Bupivacine (P<0.05). The 
children in this group also experienced longer duration of analgesia and 
therefore lesser amount  of rescue analgesia consumed.  Quality of sleep and the 
overall physical activity of the children in the Dexmedetomidine  group was 
very encouraging.  Caudally administered Dexemedetomidine  (1 μg/kg), 
combined with Bupivacaine, was associated with an extended duration of post-
operative pain relief. 
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MATERIALS AND METHOD 
SOURCE OF DATA: 
Patients undergoing abdominal surgeries done under general anesthesia at 
Govt. Kilpauk  Medical College Hospital and  Govt. Royapettah Hospital , 
Chennai between February 2016 and july 2016  were assessed for inclusion and 
exclusion criteria and were included in the study only after obtaining written 
informed consent. 
SAMPLE SIZE: 60 
Sample size was determined based on  the study “  Postoperative 
analgesic efficacy of epidural Fentanyl and Neostigmine as adjuvant to 
Bupivacaine in adults undergoing  abdominal surgeries”, authored by Selcen 
Tekin et al.  published in Saudi Med J 2006 ; Vol. 27( 8): 1199- 1203. In this 
study the total analgesic consumption was significantly higher in Group B 
147.7±7.2 ml, when compared to Group N 123.4 ± 6.2 ml  and in Group F 106± 
8.3 ml, with a Standard Deviation of about 7.2 ml. 
DESCRIPTION: 
The formula for determining sample size is given as:    
Where 
n = Sample size 
σ = Population standard deviation 
e = Margin of error 
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Z = The value for the given confidence interval 
• The confidence level is estimated at 95% 
• Standard deviation 58  
• With a z value of 1.96 
• The confidence interval or margin of error is estimated at +/-15 
•  Assuming that 80 percent as power of the study, minimum sample    size 
required for the study was calculated to be 58. 
In our study 60 subjects were chosen  
(n=20 in Group B arm, n= 20 in Group F and n=20 in Group N arm) 
STUDY DESIGN: 
A prospective,  Non –Randomized, Triple Arm, Single- Blind, Controlled  
study. 
INCLUSION CRITERIA: 
1) Patients undergoing elective abdominal surgeries under general 
anaesthesia. 
2) Age between 20 to 60 years. 
3) Males and females. 
4) ASA class I and II. 
5) Patients who have given valid informed consent. 
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EXCLUSION CRITERIA: 
1) Patients not satisfying inclusion criteria. 
2) Patients with an allergy or sensitivity to opioid group of drugs and local 
anesthetics.  
3) Patients with spinal deformities. 
4) Any contraindication to epidural anesthesia. 
5) Patients with neurological disorders. 
6) Impaired ability to communicate (e.g., confusion, poor hearing or 
language barrier). 
7) Patients who are unconscious or severely ill. 
8) Pregnant patients. 
9) Patients with Coagulation disorders. 
MATERIALS: 
1) Boyles’ apparatus 
2) Laryngoscope with different blade sizes 
3) Other airway gadgets used in case of difficult intubation 
4) Endotracheal tubes 
5) Drugs for administering general anesthesia 
6) Epidural needle and catheter set 
7) Glass syringe 
8) Inj. Fentanyl , available as ampoules( one ampoule contains  2ml, each 
ml contains 50 mcg of Fentanyl) 
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9) Inj. Neostigmine  , available as ampoules ( one ampoule contains 1 ml ,  
each ml contains 500 mcg of Neostigmine) 
10) Inj. Bupivacaine, available as vials in concentration of 0.5%  ( each vial 
contains 20 ml, each ml contains 5 mg of Bupivacaine) 
METHODOLOGY:  
Patients in the above mentioned inclusion criteria selected were 
counselled about the risks and benefits involved in the study. After getting 
consent, patients who were  willing to be included in the study were enrolled 
and analyzed. A total of 60 patients were included in the study. Patients were 
divided into three groups of 20 in each based on computerized random number 
into group B, group F and group N . The patients in Group B received 0.125% 
Bupivacaine  ,the patients in Group F  received solution containing 0.125%  
Bupivacaine with Fentanyl (1mcg/kg) and patients in Group N  received0.125%  
Bupivacaine with Neostigmine ( 10 mcg/kg) epidurally at the end of the 
procedure ( which was around 200 mins in all the cases ). The total volume of 
drug in either group was 10ml.  
This study was designed as a prospective, comparative study. Patients 
were  preoperatively evaluated, clinically examined and proper investigations 
were done prior to the assessment. Procedures were explained in detail and 
written consent was obtained. Routine monitoring included ECG, Pulse 
Oximetry, NIBP. Intravenous cannulation was done with 18 G venflon.  
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Patient was premedicated with Inj. Glycopyrrolate  6mcg/kg IV, Inj. 
Midazolam 0.01mg/kg IV, Inj. Fentanyl 2 mcg/kg IV. Under sterile aseptic 
precautions, with patient in right lateral position , at the level of T12-L1 
intervertebral space, after subcutaneous infiltration of 2ml of 2% Lignocaine, 
using 18G Tuohy epidural needle, epidural space was identified by loss of 
resistance technique, and 20 G catheter was threaded in via the needle. After 
ensuring that blood or cerebrospinal fluid was not aspirated via catheter, 3ml of 
2% Lignocaine with Adrenaline (1:2,00,000) dilution was administered via it. 
Patient was then made to lie in supine position.  Preoxygenated with 
100% oxygen for at least 3 minutes under closed circuit. Then induced with 
Injection Propofol 2mg/kg and Atracurium 0.5mg/kg was administered. 
Intubated with endotracheal tube of appropriate size for the patient and secured 
in a proper manner. Maintenance was done with Nitrous oxide and Oxygen in 
the ratio of 2:1 and Sevoflurane. 
The epidural drug administration was given at the start of incisional 
wound closure according to the group the patient belongs to. The total volume 
of drug in either group was 10ml. At the end of surgery, patient was extubated 
after reversal of neuromuscular blockade by injecting Neostigmine (50mcg/kg) 
and Glycopyrrolate (10mcg/kg) and shifted to postoperative care unit. 
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ASSESSMENT CRITERIA GROUP B GROUP F GROUP  N 
Visual analogue pain scale     
Time for first rescue 
analgesia/ Duration of 
analgesia 
   
Ramsay sedation score    
Postoperative nausea and 
vomiting 
   
Heart rate    
Blood pressure    
Respiratory rate    
Oxygen saturation    
Pruritus    
 
METHOD OF COLLECTION OF DATA 
60  patients enrolled in the study who underwent elective abdominal 
surgeries under general anesthesia were assessed post-operatively. The 
parameters mentioned above in the table were recorded at every 15 minutes for 
the first two hours and then hourly upto 12 hours in the postoperative ward. The 
epidural bolus dose  at the end of the procedure was 10ml of 0.125% 
Bupivacaine in group B with normal saline, 10ml  of 0.125% Bupivacaine with 
Fentanyl 1mcg/kg in group F and 10 ml of 0.125% Bupivacaine with 
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Neostigmine 10 mcg/ kg in group N. Duration of analgesia was calculated from 
the time of epidural bolus to the time when first top up dose is required. Also the 
number of episodes of vomiting and number of patients complaining of pruritus 
was recorded. 
STATISTICAL ANALYSIS: 
Descriptive statistics was done for all data and reported in terms of 
mean values and percentages. Suitable statistical tests of comparison was done. 
Continuous variables was  analysed with the unpaired t test and ANOVA single 
factor test. Categorical variables was analysed with the Chi-Square Test and 
Fisher Exact Test. Statistical significance was taken as P<0.05. The data was 
analysed using SPSS version 16 and Microsoft Excel 2007. 
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OBSERVATIONS AND RESULTS 
The study population consisted of 60 patients posted for elective 
abdominal surgery under general anaesthesia with epidural block . They were 
divided into three groups of 20 each. All these patients received epidural bolus 
doses at the end of the procedure. The patients in Group B received 0.125% 
Bupivacaine with normal saline  ,the patients in Group F received solution 
containing 0.125%  Bupivacaine with Fentanyl (1mcg/kg) and patients in Group 
N received 0.125%  Bupivacaine with Neostigmine ( 10mcg/kg) epidurally at 
the end of the procedure. The total volume of drug in either group will be 10ml. 
Patient characteristics involved were age, gender, weight and ASA grade. 
The pre -operative heart rate, respiratory rate, mean arterial blood pressure and 
oxygen saturation were recorded prior to administering epidural block. After 
that patient is allowed to undergo surgery under general anaesthesia. Patients’ 
vitals including  heart rate, respiratory rate, mean arterial blood pressure and 
oxygen saturation are measured at the following time intervals 15, 30, 45, 60, 
90, 120, 180 mins and hourly till 12 hours in the post operative period. Most of 
the surgeries were completed by around 180 – 210 mins. Time for first rescue 
analgesia, post -operative  nausea and vomiting, pruritus, visual analogue scale 
and Ramsay sedation score were observed hourly till 12 hours into the post 
operative period.  
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The following observations were made during the course of the study.  
Table 1 and Figure 1 shows the sex difference among the patients in the three 
groups. The association between gender status and intervention groups is 
considered to be  insignificant since p value is > 0.05.   
Table 1: Shows the sex difference among the patients in the three groups.  
Group 
GENDER STATUS 
Chi square P value 
Male Female 
Bupivacaine 6 14 
0.16 0.921 
Bupivacaine with 
Fentanyl 
5 15 
Bupivacaine with 
Neostigmine 
6 14 
 
Figure 1: Shows the sex difference among the patients in the three groups. 
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Table 2 and Figure 2 shows the age distribution among the patients in the three 
groups. The mean weight in Group B was 36.65 ± 2.04, Group F 35.55 ± 1.79 
was and Group N was 35.45 ± 1.80.The association between age distribution 
and intervention groups is considered to be non significant since  
p value is > 0.05.    
Table 2 : Shows Age distribution among the patients in the three groups. 
Parameter Bupivacaine 
Bupivacaine 
with 
Fentanyl 
Bupivacaine 
with 
Neostigmine 
 
F value 
 
P 
value 
Age 36.65 ± 2.04 35.55 ± 1.79 35.45 ± 1.80 0.125 0.883 
 
Figure 2 : Shows Age distribution among the patients in the three groups. 
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Table 3 and Figure 3  shows the Weight distribution among the patients 
in the three groups. The mean weight in Group B was 61.35 ± 1.60, Group F 
was 58.85 ± 1.57 and Group N was 61.35 ± 1.39. The association between 
weight distribution and intervention groups is considered to be non significant 
since p value is > 0.05 as per unpaired t test.    
Table 3 : Shows  Weight distribution among the patients in the three groups. 
Parameters Bupivacaine 
Bupivacaine 
with 
Fentanyl 
Bupivacaine 
with 
Neostigmine 
F value P value 
Weight 61.35 ± 1.60 58.85 ± 1.57 61.35 ± 1.39 0.900 0.412 
 
Figure 3 : Shows Weight distribution among the patients in the three groups. 
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Table 4 and Figure 4 shows that the Mean time for first rescue 
analgesia in Group B was 104.75 ± 1.60, Group F was 289.25 ± 3.23 and Group 
N was 261.00 ± 4.13. The three groups were comparable with respect to the time 
for first rescue analgesia. Analysis of variants in table 1 and Figure 1 showed 
they were highly statistically significant. ( p< 0.05 ) . 
Table 4 : Comparison of average time for  first rescue analgesia in Group 
B, Group F and Group N . 
TIME FOR FIRST RESCUE ANALGESIA  
Heart rate Bupivacaine 
Bupivacaine 
with 
Fentanyl 
Bupivacaine 
with 
Neostigmine 
F value P value 
Time for first 
rescue Analgesia 
104.75 ± 1.60 289.25 ± 3.23 261.00 ± 4.13 986.026 0.0001 
         
Figure 4 : Comparison of average time for first rescue analgesia in Group 
B, Group F and Group N . 
 
0 
50 
100 
150 
200 
250 
300 
Bupivacaine Bupivacaine with 
Fentanyl 
Bupivacaine with 
Neostigmine 
TIME FOR FIRST RESCUE ANALGESIA 
59 
 
Table 5 and figure 5 shows the heart rate variation in the three groups. 
The three groups were comparable with respect to heart rate changes. There was 
no statistically significant difference in heart rate at 15, 30, 45, 60, 90, 120 and 
180 mins till the end of surgery (which was around 200 mins in all the three 
groups ). But, there was a statistically significant difference in heart rate ( p< 
0.05 ) at 360 , 480 and 540 mins in the post operative period.  
Table 5 : Comparison of heart rate changes in Group B, Group F and Group N 
. 
Heart rate Bupivacaine 
Bupivacaine 
with 
Fentanyl 
Bupivacaine 
with 
Neostigmine 
F value P value 
Baseline 81.55 ± 2.41 80.30 ± 2.07 82.25 ± 2.06 0.204 0.816 
15 min 94.60 ± 2.89 94.00 ± 2.81 95.75 ± 2.27 0.111 0.895 
30 min 91.60 ± 2.92 85.30 ± 2.61 89.35 ± 2.65 1.369 0.263 
45 min 82.80 ± 2.04 80.80 ± 2.12 83.15 ± 2.24 0.353 0.704 
60 min 83.00 ± 2.32 78.05 ± 2.28 79.65 ± 2.21 1.240 0.297 
75 min 79.70 ± 2.11 77.95 ± 1.94 80.25 ± 2.07 0.347 0.709 
90 min 80.65 ± 1.71 77.20 ± 1.68 79.40 ± 1.75 1.039 0.360 
120 min 81.70 ± 2.40 77.00 ± 2.20 79.25 ± 2.18 1.078 0.347 
180 min 84.60 ± 2.16 80.30 ± 2.83 83.00 ± 2.14 0.823 0.444 
240 min 83.05 ± 2.30 77.45 ± 2.66 78.80 ± 1.94 1.591 0.213 
300 min 82.40 ± 2.36 73.30 ± 2.33 77.80 ± 1.87 4.290 0.018 
360 min 83.30 ± 2.32 70.85 ± 1.88 77.70 ± 2.06 8.888 0.0001 
420 min 83.45 ± 2.13 70.80 ± 1.91 77.05 ± 2.08 9.596 0.0001 
480 min 82.05 ± 2.20 71.40 ± 1.71 77.65 ± 2.05 7.166 0.002 
540 min 80.40 ± 2.35 75.00 ± 2.33 82.80 ± 2.11 3.114 0.052 
600 min 80.50 ± 2.05 78.40 ± 2.35 82.65 ± 2.16 0.944 0.395 
660 min 79.55 ± 1.86 77.90 ±2.40 81.15 ± 1.93 0.613 0.545 
720 min 80.25 ± 1.99 78.20 ± 2.21 81.70 ± 2.04 0.714 0.494 
60 
 
Figure 5: Comparison of heart rate changes in Group B, Group F and Group N 
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Table  6 and figure 6 shows the Mean arterial blood pressure variation in 
the three groups. The three groups were comparable with respect to arterial 
blood pressure changes. There was no statistically significant difference in mean 
arterial blood pressure either at 15, 30, 45, 60 , 90, 120, 180 mins till the end of 
surgery ( which was around 200 mins in all the three groups ) or hourly into the 
post – operative period till 12 hours. 
Table 6 : Comparison of MAP changes in Group B, Group F and Group N. 
Mean arterial 
BP 
Bupivacaine 
Bupivacaine 
with Fentanyl 
Bupivacaine 
with 
Neostigmine 
F value P value 
Baseline 90.45 ± 2.34 90.95 ± 2.06 91.55 ± 2.09 0.065 0.937 
15 min 80.50 ± 1.85 83.05 ± 1.81 83.35 ± 1.70 0.768 0.468 
30 min 84.15 ± 1.58 84.60 ± 1.67 84.90 ± 1.75 0.051 0.950 
45 min 84.30 ± 1.34 86.60 ± 1.62 86.55 ± 1.71 0.702 0.500 
60 min 84.95 ± 1.46 86.30 ± 1.61 86.15 ± 1.77 0.209 0.812 
75 min 84.80 ± 1.34 86.70 ± 1.77 86.75 ± 1.90 0.434 0.650 
90 min 84.90 ± 1.42 86.15 ± 1.76 86.35 ± 1.87 0.215 0.807 
120 min 84.65 ± 1.45 86.20 ± 1.67 86.80 ± 1.87 0.441 0.646 
180 min 87.35 ± 1.93 86.75 ± 1.65 86.80 ± 1.87 0.034 0.967 
240 min 87.60 ± 2.41 87.15 ± 1.70 87.30 ± 1.97 0.013 0.988 
300 min 83.85 ± 1.65 86.45 ± 1.74 86.60 ± 1.91 0.764 0.471 
360 min 85.95 ± 1.86 86.50 ± 1.72 86.60 ± 1.91 0.037 0.964 
420 min 86.25 ± 1.84 86.95 ± 1.68 86.60 ± 1.93 0.037 0.964 
480 min 86.35 ± 1.84 87.15 ± 1.75 87.40 ± 1.94 0.088 0.916 
540 min 86.65 ± 1.87 87.35 ± 1.69 87.85 ± 1.96 0.107 0.899 
600 min 86.40 ± 1.67 87.55 ± 1.91 88.15 ± 2.12 0.216 0.806 
660 min 86.55 ± 1.91 87.40 ± 1.82 87.00 ± 1.90 0.051 0.950 
720 min 86.45 ± 1.81 87.65 ± 1.87 87.15 ± 1.99 0.102 0.903 
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Figure 6: Comparison of MAP changes in Group B, Group F and Group N. 
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Table  7 and figure 7 shows the respiratory rate variation in the three 
groups. The three groups were comparable with respect to respiratory rate 
changes. There was no statistically significant difference in heart rate at 15, 30, 
45, 60 , 90, 120 and 180 mins till the end of surgery ( which was around 200 
mins in all the three groups ). But, there was a statistically significant difference 
in respiratory rate ( p< 0.05 ) at 360 mins in the post operative period. 
Table 7: Comparison of respiratory rate changes in Group B, Group F and 
Group N 
Respiratory 
Rate 
Bupivacaine 
Bupivacaine 
with Fentanyl 
Bupivacaine 
with 
Neostigmine 
F value P value 
Baseline 12.55 ± 0.33 12.50 ± 0.28 12.10 ± 0.37 0.570 0.569 
15 min 12.70 ± 0.27 12.70 ± 0.27 12.60 ± 0.22 0.051 0.951 
30 min 12.00 ± 0.07 12.00 ± 0.07 12.00 ± 0.07 0.00 1.00 
45 min 12.00 ± 0.00 12.00 ± 0.00 12.00 ± 0.00 0.00 1.00 
60 min 12.00 ± 0.00 12.00 ± 0.00 11.95 ± 0.05 1.000 0.374 
75 min 12.00 ± 0.00 12.00 ± 0.00 12.00 ± 0.00 0.00 1.00 
90 min 12.05 ± 0.90 12.05 ± 0.09 12.05 ± 0.09 0.00 1.00 
120 min 12.45 ± 0.28 12.45 ± 0.28 12.45 ± 0.28 0.00 1.00 
180 min 13.20 ± 0.36 13.15 ± 0.36 13.30 ± 0.44 0.039 0.962 
240 min 10.95 ± 0.17 11.05 ± 0.17 11.00 ± 0.19 0.079 0.924 
300 min 11.15 ± 0.25 11.10 ± 0.26 11.15 ± 0.27 0.012 0.988 
360 min 12.70 ± 0.53 11.35 ± 0.18 11.85 ± 0.20 3.984 0.024 
420 min 13.25 ± 0.41 12.25 ± 0.25 12.70 ± 0.32 2.275 0.112 
480 min 12.85 ± 0.30 12.80 ± 0.30 13.50 ± 0.48 1.095 0.341 
540 min 13.10 ± 0.28 13.90 ± 0.34 13.30 ± 0.27 1.941 0.153 
600 min 12.90 ± 0.24 13.00 ± 0.24 13.05 ± 0.26 0.097 0.908 
660 min 12.95 ± 0.28 13.00 ± 0.29 13.00 ± 0.27 0.011 0.989 
720 min 12.80 ± 0.24 12.85 ± 0.22 12.70 ± 0.23 0.111 0.895 
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Figure 7: Comparison of respiratory rate changes in Group B, Group F 
and Group N. 
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Table  8 and figure 8 shows the oxygen saturation  variation in the three 
groups. The three groups were comparable with respect to oxygen saturation 
changes. There was no statistically significant difference in oxygen saturation at 
15, 30, 45, 60 , 90, 120 and 180 mins till the end of surgery ( which was around 
200 mins in all the three groups ). But, there was a statistically significant 
difference in oxygen saturation ( p< 0.05 ) at 360 mins in the post operative 
period. 
Table 8: Comparison of oxygen saturation changes in Group B,  
Group F and Group N. 
Oxygen 
saturation 
Bupivacaine 
Bupivacaine with 
Fentanyl 
Bupivacaine with 
Neostigmine 
 
F value 
 
P value 
Baseline 99.65 ± 0.13 99.75 ± 0.10 99.90 ± 0.07 1.492 0.234 
15 min 100.00 ± 0.00 100.00 ± 0.00 100.00 ± 0.00 0.00 1.00 
30 min 99.95 ± 0.05 99.90 ± 0.07 99.95 ± 0.05 0.257 0.774 
45 min 99.95 ± 0.05 100.00 ± 0.00 100.00 ± 0.00 1.000 0.374 
60 min 99.90 ± 0.07 99.85 ± 0.08 99.95 ± 0.05 0.538 0.587 
75 min 100.00 ± 0.00 99.90 ± 0.07 99.95 ± 0.05 1.036 0.361 
90 min 100.00 ± 0.00 100.00 ± 0.00 100.00 ± 0.00 0.00 1.00 
120 min 99.90 ± 0.07 99.95 ± 0.05 100.00 ± 0.00 1.036 0.361 
180 min 100.00 ± 0.00 99.95 ± 0.05 99.85 ± 0.08 1.900 0.159 
240 min 100.00 ± 0.00 100.00 ± 0.00 99.90 ± 0.07 2.111 0.130 
300 min 100.00 ± 0.00 100.00 ± 0.00 100.00 ± 0.00 0.00 1.00 
360 min 99.10 ± 0.22 99.90 ± 0.07 100.00 ± 0.00 14.153 0.0001 
420 min 99.65 ± 0.13 99.85 ± 0.08 99.75 ± 0.12 0.768 0.469 
480 min 99.75 ± 0.10 99.75 ± 0.12 99.85 ± 0.08 0.315 0.731 
540 min 99.95 ± 0.05 99.95 ± 0.05 99.95 ± 0.05 0.00 1.00 
600 min 99.95 ± 0.05 99.95 ± 0.05 99.95 ± 0.05 0.00 1.00 
660 min 100.00 ± 0.00 99.85 ± 0.08 100.00 ± 0.00 2.353 0.142 
720 min 99.95 ± 0.05 99.85 ± 0.08 99.90 ± 0.07 0.538 0.587 
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Figure  8: Comparison of oxygen saturation changes in Group B,  
Group F and Group N. 
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Table  9 and figure 9 shows visual analogue scale variation in the three 
groups. The three groups were comparable with respect to visual analogue scale 
changes. Analysis of variants in table 6 and Figure 6 showed they were highly 
statistically significant. ( p< 0.05 ) 
Table  9: Comparison of visual analogue scale in Group B,  
Group F and Group N. 
VISUAL ANALOGUE SCALE CHANGES 
 
 
VAS 
 
Bupivacaine 
Bupivacaine 
with 
Fentanyl 
Bupivacaine 
with 
Neostigmine 
 
F value 
 
P value 
300 min 3.55 ± 0.95 0.25 ± 0.12 0.45 ± 0.14 10.912 0.0001 
360 min 7.85 ± 0.41 0.60 ± 0.18 1.15 ± 0.17 211.302 0.0001 
420 min 5.50 ± 0.36 0.75 ± 0.16 1.25 ± 0.18 110.160 0.0001 
480 min 4.75 ± 0.23 1.55 ± 0.44 3.75 ± 0.68 11.297 0.0001 
540 min 4.80 ± 0.26 6.30 ± 0.65 6.55 ± 0.47 3.806 0.028 
600 min 4.60 ± 0.26 4.80 ± 0.42 4.70 ± 0.29 0.092 0.912 
660 min 4.80 ± 0.24 3.90 ± 0.24 3.90 ± 0.22 5.062 0.009 
720 min 4.55 ± 0.24 3.60 ± 0.29 4.05 ± 0.22 3.541 0.036 
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Figure  9: Comparison of visual analogue scale in Group B,  
Group F and Group N. 
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Table  10 and figure 10 shows Ramsay sedation score variation in the 
three groups. The three groups were comparable with respect to Ramsay 
sedation score changes. Analysis of variants in table 7 and Figure 7 showed they 
were highly statistically significant. ( p< 0.05 ). 
Table  10: Comparison of Ramsay sedation score in Group B, Group F and 
Group N. 
RAMSAY SEDATION SCORE CHANGES 
Ramsay 
Sedation 
score 
 
Bupivacaine 
Bupivacaine 
with 
Fentanyl 
Bupivacaine 
with 
Neostigmine 
F value P 
value 
Baseline 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 0.00 1.00 
240 min 1.85 ± 0.08 2.60 ± 0.15 2.10 ± 0.07 12.643 0.0001 
300 min 2.00 ± 0.00 3.15 ± 0.15 2.00 ± 0.00 58.778 0.0001 
360 min 2.00 ± 0.00 3.45 ± 0.11 2.00 ± 0.00 161.404 0.0001 
420 min 2.00 ± 0.00 3.10 ± 0.07 2.00 ± 0.00 255.444 0.0001 
480 min 2.00 ± 0.00 2.60 ± 0.11 2.00 ± 0.00 28.500 0.0001 
540 min 2.00 ± 0.00 2.35 ± 0.11 2.00 ± 0.00 10.231 0.0001 
600 min 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 0.00 1.00 
660 min 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 0.00 1.00 
720 min 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 0.00 1.00 
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Figure 10: Comparison of Ramsay sedation score in Group B, Group F and 
Group N. 
RAMSAY SEDATION SCORE CHANGES 
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Table 11 and Figure 11 shows that the number of patients who had post 
operative nausea and vomiting was 13 in Group F,  1 in Group N and none in 
Group B . The three groups were comparable with respect to patients who had 
post operative nausea and vomiting . Analysis of variants in table 8 and Figure 8 
showed they were highly statistically significant. ( p< 0.05 ) 
Table  11: Comparison of number of patients with post operative nausea 
and vomiting  in Group B, Group F and Group N. 
 
Group 
Nausea / vomiting 
Chi square P value 
Present Absent 
Bupivacaine 0 20 
29.25 0.0001 Bupivacaine with Fentanyl 13 7 
Bupivacaine with  Neostigmine 1 19 
 
Figure  11: Comparison of number of patients with post operative nausea 
and vomiting  in Group B, Group F and Group N.  
  
0
2
4
6
8
10
12
14
16
18
20
Bupivacaine Bupivacaine with
Fentanyl
Bupivacaine with
Neostigmine
Nausea / vomiting 
Present
Absent
72 
 
Table 12 and Figure 12 shows that the number of patients who had 
pruritus was 12  in Group F and none in Group B and Group N. The three 
groups were comparable with respect to patients who had pruritus . Analysis of 
variants in table 8 and Figure 8 showed they were highly statistically significant. 
( p< 0.05 ). 
Table  12: Comparison of number of patients with pruritus in Group B, 
Group F and Group N. 
PRURITUS 
 
Group 
Pruritus  
Chi square 
 
P value Present Absent 
Bupivacaine 0 20 
30.00 0.0001 Bupivacaine with Fentanyl 12 8 
Bupivacaine with Neostigmine 0 20 
 
Figure  12: Comparison of number of patients with post operative nausea 
and vomiting  in Group B, Group F and Group N. 
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DISCUSSION 
The results of our study showed there was no significant difference in age 
distribution, weight distribution and gender status among the three groups in our 
study (p value > 0.05).   
The time for first rescue analgesia in Group B is 104.75 ± 1.60, Group F 
is 289.25 ± 3.23 and Group N was 261.00 ± 4.13. Based on this evaluation, the 
duration of post operative analgesia in  Group F and Group N was found to be 
much higher when compared to Group B.  
The study done by Tekin S et al. (9) comparing  the post operative  
analgesic activity of the Neostigmine and Fentanyl when used as an additive to 
Bupivacaine  in patients undergoing abdominal hysterectomy  under general 
anaesthesia was similar to our study and substantiating to our results. 
One another similar study which was consistent with our results was 
done by Fyneface-Ogan S et al. (7), who compared Neostigmine as an adjuvant 
to caudal Bupivacaine and caudal Bupivacaine alone for postoperative analgesia 
in children. They found that the patients  in Bupivacaine – Neostigmine group 
required only very low doses of analgesia in the post operative period. (p < 
0.001). 
In a similar study by Ross VH et al. (16) where they did a randomized 
controlled study on a group of obstetric patients using Bupivacaine and 
Neostigmine for elective caesarean section. It was found that epidural 
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Neostigmine infusion reduced Bupivacaine requirement by 19% in all patients 
and 25% in those with >4 h of treatment (P < 0.05 for both), which was similar 
and consistent with our findings. It was also found that these patients also 
experienced mild sedation similar to our study. 
Similarly , another study done by Nakayama. M et al.(40) to evaluate  the 
analgesic effects of epidural Neostigmine in adult patients undergoing 
abdominal hysterectomy also validated our results. Here the duration of post op 
analgesia was higher in the 10 μg group than 5 μg group.  
Another study which was consistent with our results was done by 
Lauretti GR et al. (14) to compare the postoperative analgesic property of  intra-
articular and epidural Neostigmine in patients undergoing knee surgery under 
combined Spinal – epidural  anaesthesia. The time (min) for first rescue 
analgesia was much longer in both the 1 ug /kg epidural Neostigmine ( EG 
)Group and 500 ug intra – arterial Neostigmine ( AG ) Groups. (p<0.05). 
In our study, the number of patients who had pruritus was 12 in Group F 
and none in Group B and Group N. Analysis showed  that they were highly 
statistically significant. ( p< 0.05 ). It was substantiated by a study conducted by 
Cossu AP et al. (29) where Neostigmine was added as an adjuvant to local 
anaesthetics for neuraxial blockade in obstetric patients. Pruritus was also very 
rare in patients who received epidural Neostigmine.  
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Hany A. Shehab and Samar A. Salman (32) conducted a study in women 
who underwent open abdominal hysterectomy for dysfunctional uterine bleeding 
under epidural combined with general anaesthesia. The results were similar to 
our study where the mean duration of post operative analgesia was significantly 
longer in the Dexamethasone/Levobupivacainegroup compared with groups 
Neostigmine/ Levobupivacaine and Levobupivacaine, with significantly longer 
duration in the Neostigmine/ Levobupivacaine group compared with group 
Levobupivacaine. 
In our study , the number of patients who had post operative nausea and 
vomiting was 13 in Group F,  1 in Group N and none in Group B. Analysis 
showed  that they were highly statistically significant. ( p< 0.05 ). This was 
consistent with one prospective randomized double-blind study evaluating  low-
dose Dexmedetomidine and Neostigmine with Bupivacaine for postoperative 
analgesia in orthopedic surgeries done by Sharma. A et al. ( 1 ). It showed that 
epidurally administered Dexmedetomidine and Neostigmine exhibit synergism 
in analgesic action. Neostigmine did not cause any significant gastrointestinal 
side effects like nausea and vomiting.  
Getu Ataro et al. (43) conducted  a comparative study between caudal 
Neostigmine added to Bupivacaine  and caudal Bupivacaine alone on paediatric 
patients undergoing elective orthopaedic surgery under general anaesthesia.  
They concluded that the duration of analgesia and time to first rescue analgesia 
was longer in group where Neostigmine was added to caudal Bupivacaine. The 
values were also highly significant (p <0.003). Thus validating our results. 
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SUMMARY 
Out of 60 patients included with 20 each in three groups in this study, 
Group B received 10 ml of  0.125% Bupivacaine with normal saline , the 
patients in Group F received 10 ml  of 0.125%  Bupivacaine with Fentanyl 
(1mcg/kg) and patients in Group N received 10 ml of 0.125%  Bupivacaine with 
Neostigmine ( 10mcg/kg) for elective abdominal surgeries under general 
anaesthesia at the end of the procedure.  
The pre operative hemodynamic parameters were comparable between 
the three groups. There was minimal intra – operative variations in heart rate , 
mean arterial blood pressure , respiratory rate and oxygen saturation in all the 
cases.  
The duration of analgesia i.e, time interval between epidural drug bolus 
and time for first rescue analgesia was higher in Bupivacaine +Fentanyl group 
and Bupivacaine +Neostigmine Group  when compared to the Group which 
received only Bupivacaine. The post operative variations in heart rate , mean 
arterial blood pressure , respiratory rate and oxygen saturation were also 
comparable between the three groups. The parameters were also statistically 
significant when compared to the baseline values.  
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Post operative sedation and visual analogue scores were also significantly 
higher in Group F and Group N when compared to the Group B. 
Adverse effects like pruritus and gastrointestinal side effects like nausea 
and vomiting were significantly less in Group N and Group B , but increased in 
Group F where Fentanyl was used.  
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CONCLUSION 
The duration of post operative epidural analgesia was higher when 
either Fentanyl or Neostigmine was used as an adjuvant to epidural Bupivacaine 
than with Bupivacaine alone. However, because of adverse effects like pruritus 
and  gastrointestinal side effects  like nausea and vomiting with Fentanyl, 
epidural Neostigmine can be preferred to epidural Fentanyl as an adjuvant to 
Bupivacaine since the duration of post operative analgesia was comparatively 
similar in both these Groups  ( Group F and Group N ). 
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LIMITATIONS  
 
1. Further studies are required to study the efficacy of epidural Neostigmine 
for post operative analgesia using different doses of Neostigmine. 
2. The efficacy of Epidural Neostigmine when used with other local 
anaesthetics like Ropivacaine must be studied. 
3. In our study epidural Neostigmine was used only postoperatively. We 
must also study the intra-operative hemodynamic changes produced 
when epidural Neostigmine is coadministered with local anaesthetics 
before the start of the surgery. 
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PROFORMA 
“A STUDY ON POSTOPERATIVE ANALGESIC EFFICACY   OF   
EPIDURAL BUPIVACAINE, BUPIVACAINE WITH FENTANYL AND 
BUPIVACAINE WITH  NEOSTIGMINE IN ADULTS UNDERGOING 
ABDOMINAL SURGERIES UNDER GENERAL ANAESTHESIA” 
Name:    Age/ Gender:    IP.Number: 
Weight:   Diagnosis:    Plan of surgery: 
Date of surgery:    ASA Physical status: 
Comorbidities:    Drug history: 
Group ( Tick any one ):  
            Group B : 10 ml of 0.125% Bupivacaine. 
                        Group F : 10ml of 0.125%  Bupivacaine with Fentanyl(1μg/kg). 
     Group N: 10 ml of 0.125% Bupivacaine with 
Neostigmine(101μg/kg). 
Medications: 
Inj. Ondansetron  8 mg IV if patient develops nausea and vomiting. 
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OBSERVATION : 
Duration of surgery: 
Time ( from induction of 
anaesthesia to 12 hours in the 
postoperative period) 
Heart 
rate 
MAP Respiratory    
rate 
Oxygen 
saturation 
Before start of surgery / baseline     
15 mins     
30 mins     
45 mins     
60 mins     
90 mins     
120 mins     
180 mins     
240 mins     
300 mins     
360 mins     
420 mins     
480 mins     
540 mins     
600 mins     
660 mins     
720 mins     
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VISUAL ANALOGUE SCALE AND RAMSAY SEDATION SCORE 
DURATION OF SURGERY: 
Time ( from end of 
surgery to 12 hours in 
the postoperative 
period) 
Visual 
Analogue 
Scale 
Ramsay 
Sedation 
Score 
Pruritus 
(present /+ or 
absent /-) 
Nausea and 
vomiting 
(present /+ 
or absent-) 
At the end of surgery     
180 mins     
240 mins     
300 mins     
360 mins     
420 mins     
480 mins     
540 mins     
600 mins     
660 mins     
720 mins     
 
The time for first rescue analgesia / total duration of post 
operative analgesia : 
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PATIENT CONSENT FORM 
 
STUDY: ” A STUDY ON  POSTOPERATIVE ANALGESIC 
EFFICACY OF EPIDURAL BUPIVACAINE , 
BUPIVACAINE WITH  FENTANYL AND BUPIVACAINE  
WITH NEOSTIGMINE  IN ADULTS UNDERGOING 
ABDOMINAL SURGERIES UNDER GENERAL 
ANAESTHESIA”. 
STUDY CENTRE:  GOVT. KILPAUK MEDICAL COLLEGE  
& GOVT ROYAPETTAH  HOSPITAL, CHENNAI 
PATIENT’S NAME: 
PATIENT’S AGE: 
I.P NO            : 
                        Patient may check ( √  ) these boxes 
I confirm that I understood the purpose of the procedure for 
the above study. I have the opportunity to ask question and 
all my questions and doubts have been answered to my 
complete satisfaction 
I understand that my participation in the study is voluntary 
and that I am free to withdraw at any time without giving 
reason, without my legal rights being affected. 
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I understand that the ethical committee members  and the 
regulatory authorities will need not my permission to look 
at my health records, both in respect of the current study 
and any further research that may be conducted in relation 
to it, even if I withdraw from the study I agree to this 
access. However, I understand that my identity will not be 
revealed in any information released to third parties or 
published, unless as required under the law.  
 
I agree not to restrict the use of any data or results that arise 
from the study. i agree to take part in the above study and 
to comply with the instructions given during the study and 
faithfully co operate with the study team and to 
immediately inform the study staff  if I suffer from any 
deterioration in my health or well being or any unexpected 
or unusual symptoms. 
 
I hereby consent to participate in this study. 
 
I hereby give permission to undergo complete clinical 
examination and diagnostic tests including hematological, 
biochemical, radiological tests. 
 
Signature / thumb impression:               
               
Patient’s name and address:                 
place:                     date:      
Signature of the investigator: 
Study investigator’s name:                                              
place:                        date: 
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சுய ஒப்புதல் படிவம் 
 
ஆய்வு செய்யப்படும் தலைப்பு 
         அரசு               
         அரசு             யிறு 
          க்கு பின்   குத்த   ட 
        பபொருத்தப்பட்டிருக்கு  வடிகுழொய் 
வழி                    ,    ட    
                                 
                             
                     . 
 
ஆராய்ச்ெி நிலையம்:         மருத்துவத் 
துறை,                        
மருத்துவக்கல்லூரி அரசு மருத்துவமறை, 
பென்றை  
 
பங்கு சபறுபவரின் சபயர்:        உறவு முலற: 
 
பங்கு சபறுபவரின் எண்: 
 
பங்கு சபறுபவர் இதலை (√) குறிக்கவும் 
மமமே குைிப்பிட்டுள்ள மருத்துவ ஆய்வின் 
விவரங்கள் எைக்கு விளக்கப்பட்டது. என்னுறடய 
ெந்மதகங்கறளக் மகட்கவும், அதற்கொை தகுந்த 
விளக்கங்கறளப் பபைவும் வொய்ப்பளிக்கப்பட்டது.  
நொன் இவ்வொய்வில் தன்ைிச்றெயொகத்தொன் 
பங்மகற்கிமைன். எந்தக் கொரணத்திைொமேொ எந்தக் 
கட்டத்திலும் எந்த ெட்ட ெிக்கலுக்கும் உட்படொமல் 
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நொன் இவ்வொய்வில் இருந்து விேகிக் பகொள்ளேொம் 
என்றும் அைிந்து பகொண்மடன். 
இந்த ஆய்வு ெம்மந்தமொகவும், மமலும் இது 
ெொர்ந்தஆய்வு மமற்பகொள்ளும்மபொதும், இந்த 
ஆய்வில் பங்குபபறும் மருத்துவர் என்னுறடய 
மருத்துவ அைிக்றககறளப் பொர்ப்பதற்கு என் 
அனுமதி மதறவயில்றே எை அைிந்துபகொள்கிமைன். 
நொன் ஆய்வில் இருந்து விேகிக் பகொண்டொலும் இது 
பபொருந்தும் எை அைிகிமைன். 
இந்த ஆய்வின் மூேம் கிறடக்கும் 
தகவல்கறளயும், பரிமெொதறை முடிவுகறளயும் 
மற்றும் ெிகிச்றெ பதொடர்பொை தகவல்கறளயும் 
மருத்துவர் மமற்பகொள்ளும் ஆய்வில் பயன்படுத்திக் 
பகொள்ளவும், அறதப் பிரசுரிக்கவும் என் முழு 
மைதுடன் ெம்மதிக்கிமைன். 
 
இந்த ஆய்வில் பங்கு பகொள்ள 
ஒப்புக்பகொள்கிமைன். எைக்குக் பகொடுக்கப்பட்ட 
அைிவுறரகளின் படி நடந்துபகொள்வதுடன், இந்த 
ஆய்றவ மமற்பகொள்ளும் மருத்துவ அணிக்கு 
உண்றமயுடன் இருப்மபன் என்றும் 
உறுதியளிக்கிமைன். என் உடல் நேம் 
பொதிக்கப்பட்டொமேொ அல்ேது எதிர்பொரொத 
வழக்கத்திற்கு மொைொக மநொய்க்குைி பதன்பட்டொமேொ 
உடமை அறத மருத்துவ அணியிடம் பதரிவிப்மபன் 
எை உறுதி அளிக்கிமைன். 
இந்த ஆய்வில் எைக்கு மருத்துவப் 
பரிமெொதறை,  யிறு           க்கு பின் 
  குத்த   ட         
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பபொருத்தப்பட்டிருக்கு  வடிகுழொய் வழி    
                ,    ட    
                                 
                             
                             
         பெய்து பகொள்ள நொன் முழு மைதுடன் 
ெம்மதிக்கிமைன். 
 
பங்மகற்பவரின்  றகபயொப்பம் 
.................................................................... 
  இடம் ..............................................                  மததி ........................ 
கட்றடவிரல் மரறக: 
 
பங்மகற்பவரின் பபயர் மற்றும் விேொெம் 
........................................................................................................................
........................... 
ஆய்வொளரின் றகபயொப்பம் 
..........................................................................  
இடம் .................................................                  மததி ..................... 
ஆய்வொளரின் பபயர் 
.......................................................................................... 
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PARTICIPANTS’ INFORMATION SHEET 
Investigator   : - Dr.B. SRIDHARAN 
Name of the participant : - 
Title:   ” A STUDY ON  POSTOPERATIVE ANALGESIC 
EFFICACY OF EPIDURAL BUPIVACAINE , BUPIVACAINE 
WITH  FENTANYL AND BUPIVACAINE  WITH NEOSTIGMINE  
IN ADULTS UNDERGOING ABDOMINAL SURGERIES UNDER 
GENERAL ANAESTHESIA”. 
You are invited to take part in this research study. We have got approval 
from the IEC. You are asked to participate because you satisfy the 
eligibility criteria. 
What is the purpose of this research? 
In this study, efficacy of epidural  Fentanyl and Neostigmine as 
adjuvant to Bupivacaine in postoperative analgesia will be evaluated so 
that the patient will have increased duration of analgesia, improved 
respiratory function, reduced requirement of epidural Bupivacaine and 
reduced postoperative NSAID and opioid requirements. 
BENEFITS: 
  This study will help us in determining how Neostigmine 
when given through epidural route prolongs the post operative pain free 
duration, its role in reducing pain scores.   It helps in reducing the number 
of epidural top up doses get reduced. Hence it decreases the amount of 
epidural Bupivacaine required to be given for analgesia in the 
postoperative period.  It also helps in reducing the requirements of other 
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opioid analgesic drugs and NSAIDS given via systemic route in the 
postoperative period which causes many side effects like nausea, 
vomiting, itching, respiratory depression.  
DISCOMFORTS AND RISKS: 
          Epidural Fentanyl  may also cause nausea, vomting, pruritus 
and dizziness in some patients.  
CONFIDENTIALITY: 
                 Patients who participated in the study and their details will be 
maintained confidentially and at any cost, those details will not be let out 
RIGHT TO WITHDRAW : 
                    Patients  will not be forced to complete the study. At any cost, 
in such circumstances the treatment  will not be compromised. 
 
 
Date :     Signature of the investigator:  
Place : 
Signature/Thumb impression of   
 the participant 
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பங்மகற்பொளர் தகவல் தொள் 
         அரசு               
         அரசு             யிறு      
     க்கு பின்   குத்த   ட         
பபொருத்தப்பட்டிருக்கு  வடிகுழொய் வழி    
                ,    ட              
                                 
                                 
                  .   
நீங்கள் இந்த ஆரொய்ச்ெியில் பங்மகற்க நொங்கள் 
விரும்புகிமைொம். இந்த ஆரொய்ச்ெியில் பங்மகற்பதொல் 
தங்களது மநொயின் ஆய்வைிக்றகமயொ அல்ேது 
ெிகிச்றெமயொ பொதிக்கப்படொது என்பறதயும் பதரிவித்துக் 
பகொள்கிமைொம். 
இந்த ஆரொய்ச்ெியின் முடிவுகறள அல்ேது 
கருத்துகறள பவளியிடும் மபொமதொ அல்ேது 
ஆரொய்ச்ெியின் மபொமதொ தங்களது பபயறரமயொ அல்ேது 
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அறடயொளங்கறளமயொ பவளியிடமொட்மடொம் 
என்பறதயும் பதரிவித்துக் பகொள்கிமைொம். 
இந்த ஆரொய்ச்ெியில் பங்மகற்பது தங்களுறடய 
விருப்பத்தின் மபரில் தொன் இருக்கிைது. மமலும் நீங்கள் 
எந்மநரமும் இந்த ஆரொய்ச்ெியில் இருந்து பின்வொங்கேொம் 
என்பறதயும் பதரிவித்துக்பகொள்கிமைொம். 
இந்த ெிைப்புப் பரிமெொதறைகளின் முடிவுகறள 
ஆரொய்ச்ெியின் மபொமதொ அல்ேது ஆரொய்ச்ெியின் 
முடிவின் மபொமதொ தங்களுக்கு அைிவிப்மபொம் 
என்பறதயும் பதரிவித்துக்மகொள்கிமைொம்.  
 
ஆரொய்ச்ெியொளர்            பங்மகற்பொளர் 
றகபயொப்பம்      றகபயொப்பம்                              
மததி: 
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KEY TO MASTER CHART 
NAUSEA AND VOMITING   PRURITUS 
0- ABSENT     0- ABSENT 
1- PRESENT     1- PRESENT 
RAMSAY SEDATION SCORE 
IF AWAKE:  
Ramsay 1 -  Anxious, agitated, restless, 
Ramsay 2  - Cooperative, oriented, tranquil, 
Ramsay 3  - Responsive to commands only, 
IF ASLEEP: 
Ramsay 4  -  Brisk response to light glabellar tap or loud auditory stimulus, 
Ramsay 5  - Sluggish response to light glabellar tap or loud auditory stimulus, 
Ramsay 6 -  No response to light glabellar tap or loud auditory stimulus 
VISUAL ANALOGUE SCALE 
 
 
 
 
SL. NO NAME AGE SEX WEIGHT ASA IP NO. SURGERY BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
1 NAGAMMAL 45 F 56 2 46543 TAH WITH BSO 86 91 82 86 81 80 84 88 84 94 96 98 82 84 78 86 80 84
2 DEVARAJ 34 M 62 1 41245 LAPOROTOMY AND WIDE LOCAL EXCISION 67 73 74 78 76 78 86 82 92 87 78 74 71 67 64 68 71 74
3 RANGANATHAN 46 M 66 2 46457 OPEN CHOLECYSTECTOMY 62 74 70 68 64 66 70 62 66 68 78 72 70 70 68 68 66 64
4 PACHYAMMAL 41 F 59 1 39991 LAPOROTOMY AND WIDE LOCAL EXCISION 98 103 108 98 96 99 91 95 92 86 90 92 92 90 90 88 92 90
5 RAJESHWARI 46 F 47 1 40012 TAH WITH BSO 84 92 98 89 91 80 83 89 86 87 84 86 83 88 88 86 82 82
6 PONGOTHAI 52 F 58 2 39994 TAH WITH BSO 68 79 76 70 74 66 66 62 70 66 62 72 68 68 68 69 70 68
7 KAVERY 34 F 62 1 45671 TOTAL ABDOMINAL HYSTERECTOMY 84 92 98 89 91 80 83 89 86 87 84 86 83 88 92 86 82 86
8 MALLIKA 37 F 60 1 38343 TOTAL ABDOMINAL HYSTERECTOMY 82 96 82 80 82 88 84 84 90 92 94 82 82 84 80 84 82 84
9 SENTHAMARAI 21 F 65 1 46101 DESMOID TUMOR EXCISION IN ANTERIOR ABDOMINAL WALL 90 114 102 89 94 88 84 89 80 85 99 95 88 87 86 86 90 84
10 PAZHANI 29 M 68 1 39800 CHOLECYSTECTOMY WITH CBD EXPLORATION 71 83 80 75 70 66 68 70 64 80 72 76 72 74 70 70 71 72
11 VICTORIA 41 F 57 2 46742 TAH WITH BSO 88 98 101 87 91 80 83 89 96 82 80 93 83 88 86 86 82 86
12 DHANDAPANI 32 M 61 1 43901 ANATOMICAL MESH REPAIR 64 85 80 64 64 65 68 60 73 60 62 61 72 65 59 60 62 60
13 VIMALA 49 F 72 2 40906 TAH WITH BSO 85 92 98 89 91 80 83 89 86 87 84 90 83 88 85 86 82 86
14 VEERAPANDI 24 M 63 1 41990 LEFT HEMICOLECTOMY 83 96 92 80 81 80 82 79 91 80 79 80 91 82 82 82 81 83
15 GOWRI 39 F 68 1 43567 TAH WITH BSO 94 109 105 89 91 90 87 89 86 87 84 86 96 88 92 92 86 88
16 KALAISELVI 41 F 54 1 38691 TAH WITH BSO 90 118 114 92 88 86 90 89 99 88 90 90 104 102 90 88 90 90
17 MUNUSAMY 36 M 58 1 37927 LAPOROTOMY AND WIDE LOCAL EXCISION 70 92 75 72 68 68 71 72 82 70 68 68 82 70 68 70 72 72
18 GANGAMMAL 39 F 66 1 41091 TAH WITH BSO 85 95 94 82 84 86 80 79 91 84 84 80 92 80 82 84 80 78
19 GANGA 28 F 76 1 37402 TOTAL ABDOMINAL HYSTERECTOMY 84 92 98 89 91 80 83 89 86 87 84 86 83 88 92 86 82 86
20 SARANYA 29 F 49 1 49904 TOTAL ABDOMINAL HYSTERECTOMY 96 118 105 90 92 88 87 89 92 104 96 99 92 90 88 85 88 88
SL. NO NAME AGE SEX WEIGHT ASA IP NO. SURGERY BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
21 ILAMATHI 28 F 43 1 31389 TOTAL ABDOMINAL HYSTERECTOMY 89 112 106 84 85 91 90 94 98 90 86 82 81 83 96 88 86 86
22 VANMATHY 41 F 58 1 32671 TAH WITH BSO 80 92 84 78 78 81 72 79 84 74 72 69 66 70 78 89 78 82
23 LAKSHMI 49 F 51 2 38768 TAH WITH BSO 68 78 72 69 62 65 68 62 63 57 58 60 60 66 68 67 64 65
24 AFRIN BANU 29 F 49 1 26391 TOTAL ABDOMINAL HYSTERECTOMY 90 105 94 94 92 90 85 84 95 98 90 84 82 83 80 86 88 86
25 THAMARAI 33 F 57 1 30092 LAPOROTOMY AND CYTOREDUCTION 88 96 90 85 80 82 84 80 84 85 84 76 75 75 87 90 84 85
26 SULOCHANA 41 F 65 2 28729 TOTAL ABDOMINAL HYSTERECTOMY 84 100 95 90 86 82 76 78 90 80 76 74 75 74 78 80 82 82
27 SENGOTAVAN 29 M 59 1 33791 OPEN CHOLECYSTECTOMY 68 74 72 69 64 68 72 62 63 60 60 58 60 62 68 62 64 64
28 BABU 36 M 63 1 29172 LAPOROTOMY AND WIDE LOCAL EXCISION 65 84 62 62 60 62 64 70 62 60 60 59 56 55 56 64 60 61
29 KALPANA 28 F 55 1 42980 LAPOROTOMY AND CYTOREDUCTION 84 99 88 89 91 80 83 89 86 80 77 73 75 74 82 85 82 84
30 ABDUL RAHEEM 39 M 71 1 30952 OPEN CHOLECYSTECTOMY 78 89 80 76 75 72 71 70 70 85 70 64 65 66 69 75 72 72
31 VINODHINI 44 F 61 2 28539 TAH WITH BSO 88 103 92 85 85 86 82 81 91 80 78 76 77 73 74 80 104 96
32 NIROSHA 49 F 54 1 47296 TAH WITH BSO 91 108 94 94 88 89 85 84 95 98 90 79 80 80 80 85 80 85
33 RAJA 24 M 64 1 39275 ANATOMICAL MESH REPAIR OF INCISIONAL HERNIA 68 74 72 69 64 68 72 62 63 60 60 62 64 66 68 62 64 64
34 JAMUL RASHI 36 F 59 1 40761 LAPOROTOMY AND EXCISION OF OVARIAN CYST 76 90 73 76 72 71 72 70 76 70 66 68 66 65 64 70 75 74
35 SAFEENA BEGUM 24 F 58 1 25735 TOTAL ABDOMINAL HYSTERECTOMY 79 101 98 84 81 80 82 88 86 76 70 72 72 74 72 86 82 86
36 RAMANI 46 F 61 2 26819 TAH WITH BSO 80 84 86 78 78 76 72 79 84 74 71 69 68 70 70 80 78 82
37 SELVI 35 F 51 1 23751 OPEN CHOLECYSTECTOMY 88 104 92 86 80 82 80 78 78 84 78 76 77 76 76 88 84 82
38 JAFFER ALI 35 M 70 1 49425 ANATOMICAL MESH REPAIR OF INCISIONAL HERNIA 64 74 70 69 66 68 66 62 60 72 59 58 58 60 58 59 64 64
39 SHAJITHA 39 F 62 1 49692 TAH WITH BSO 90 111 96 90 88 84 85 86 94 84 81 82 84 80 92 86 85 84
40 NITHYA 31 F 66 1 39016 TOTAL ABDOMINAL HYSTERECTOMY 88 102 90 89 86 82 83 82 84 82 80 76 75 76 84 86 82 80
SL. NO NAME AGE SEX WEIGHT ASA IP NO. SURGERY BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
41 JOTHI 34 F 56 1 33292 TOTAL ABDOMINAL HYSTERECTOMY 81 94 85 80 78 80 78 76 78 84 78 78 76 77 91 85 80 81
42 THAHIRA BEGUM 38 F 62 1 38724 TOTAL ABDOMINAL HYSTERECTOMY 75 92 84 74 72 73 70 68 80 70 72 72 70 71 72 80 75 72
43 ANNAPURNI 42 F 66 2 36428 TAH WITH BSO 82 96 90 80 78 76 76 75 76 84 78 77 78 76 78 84 80 80
44 PUSHPALATHA 22 F 59 1 31649 LAPOROTOMY AND EXCISION OF OVARIAN CYST 98 103 108 98 96 99 91 95 92 86 90 92 92 90 90 88 94 96
45 CHINRASU 26 M 47 1 42989 ANATOMICAL MESH REPAIR OF INCISIONAL HERNIA 74 86 80 78 70 72 70 72 76 70 72 70 68 70 76 74 75 76
46 JAYASURYA 23 F 58 2 40957 MYOMECTOMY 82 92 90 83 80 78 78 80 86 80 80 78 76 78 90 84 80 82
47 THAMEEM 36 F 62 1 29534 TOTAL ABDOMINAL HYSTERECTOMY 83 96 84 80 81 80 80 79 81 80 78 78 80 82 86 83 80 84
48 INDHIRA 41 F 60 1 38572 LAPOROTOMY AND CYTOREDUCTIVE SURGERY 94 107 105 89 91 86 87 86 86 82 84 85 86 88 92 102 96 94
49 LOGANATHAN 37 M 65 1 46301 LAPOROTOMY AND WIDE LOCAL EXCISION 70 84 78 68 68 67 70 68 80 72 68 67 68 70 72 68 76 78
50 AMBIKAI 29 F 68 1 39968 TOTAL ABDOMINAL HYSTERECTOMY 92 106 86 88 84 90 88 86 96 88 86 85 84 86 90 92 86 88
51 SAFASUL 46 F 57 2 47892 TAH WITH BSO 84 96 88 82 82 80 84 85 90 80 82 82 83 84 92 86 80 86
52 SHEIK DAMOOD 38 M 61 1 31090 LEFT HEMICOLECTOMY 91 108 94 94 88 89 85 84 90 88 86 90 88 85 90 90 89 92
53 KUPPAM 30 M 72 2 40828 CHOLECYSTECTOMY WITH CBD EXPLORATION 65 74 72 69 64 68 72 62 63 64 63 62 60 60 68 63 66 64
54 MARY 46 F 63 1 43967 TAH WITH BSO 76 90 73 76 69 71 72 72 76 70 72 68 66 65 64 70 75 74
55 SHANKAR 48 M 68 1 39686 OPEN CHOLECYSTECTOMY 79 101 98 84 81 80 82 88 86 80 80 80 79 82 88 86 82 84
56 JAYAPREETHIKA 29 F 54 1 20005 OPEN OOPHORECTOMY 92 112 110 101 85 91 92 94 98 90 88 90 88 88 90 88 87 86
57 GOMATHI 35 F 71 1 29002 TAH WITH BSO 79 92 88 78 78 81 72 79 84 74 72 78 76 74 78 89 76 76
58 MEENAKSHI 41 F 65 2 43680 TAH WITH BSO 68 78 72 69 62 65 68 62 63 60 59 58 59 60 70 67 64 65
59 SAJIK AHMED 28 M 54 1 49739 LAPOROTOMY AND WIDE LOCAL EXCISION 88 105 94 94 90 90 85 84 95 88 84 82 82 83 89 86 88 80
60 SUNDARI 43 F 59 1 39258 TAH WITH BSO 92 103 108 98 96 89 88 90 84 86 84 82 82 84 90 88 94 96
BUPIVACAINE
BUPIVACAINE WITH FENTANYL
BUPIVACAINE WITH NEOSTIGMINE
HEART RATE                                                            
HEART RATE
HEART RATE
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
1 NAGAMMAL 102 81 88 87 87 86 87 81 87 111 86 91 93 93 94 95 96 95
2 DEVARAJ 88 71 80 82 81 82 82 82 82 85 81 79 80 80 81 83 84 82
3 RANGANATHAN 95 84 85 86 85 85 85 84 90 84 81 82 81 87 88 89 90 90
4 PACHYAMMAL 80 75 81 80 81 81 80 80 88 76 77 80 80 81 79 80 80 80
5 RAJESHWARI 81 69 75 77 78 78 78 78 77 78 76 79 80 78 79 80 76 79
6 PONGOTHAI 115 80 96 96 99 95 96 98 98 113 100 109 108 107 107 103 106 106
7 KAVERY 97 82 87 88 87 87 86 88 99 89 86 85 86 93 92 89 91 90
8 MALLIKA 87 79 80 82 81 82 82 80 81 77 76 79 80 81 80 81 83 83
9 SENTHAMARAI 85 84 84 83 86 89 88 84 90 83 84 88 88 87 89 88 86 86
10 PAZHANI 97 92 93 90 91 91 90 92 108 91 90 96 92 92 91 90 91 90
11 VICTORIA 108 99 100 96 99 99 100 98 98 102 96 99 100 102 102 101 101 101
12 DHANDAPANI 93 91 88 88 89 87 88 88 90 89 90 88 88 88 90 90 91 90
13 VIMALA 83 76 75 77 78 78 78 78 78 78 77 80 80 80 80 80 76 78
14 VEERAPANDI 91 86 87 88 90 88 88 89 90 98 87 88 90 91 92 89 91 91
15 GOWRI 81 69 82 80 80 81 80 81 80 84 80 80 79 79 80 79 80 80
16 KALAISELVI 86 80 85 86 86 87 87 87 88 82 81 88 89 84 85 85 86 84
17 MUNUSAMY 102 90 87 88 87 86 90 91 89 91 96 91 94 89 90 92 91 91
18 GANGAMMAL 82 78 80 80 80 81 80 80 80 81 80 84 83 80 81 80 80 80
19 GANGA 77 70 72 76 78 77 77 77 78 80 77 77 78 77 76 77 76 76
20 SARANYA 79 74 78 76 76 76 76 77 76 80 76 76 76 78 77 77 76 77
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
21 ILAMATHI 79 72 78 80 77 78 79 80 80 78 76 76 77 77 82 78 78 80
22 VANMATHY 92 85 88 88 89 87 86 88 87 88 87 88 89 93 89 90 88 87
23 LAKSHMI 108 86 90 98 89 100 99 100 98 99 98 100 99 99 99 106 98 100
24 AFRIN BANU 95 82 88 88 88 87 86 88 88 89 87 89 90 92 88 89 91 90
25 THAMARAI 88 80 80 82 81 81 79 80 80 82 80 79 80 81 80 81 83 84
26 SULOCHANA 94 92 88 88 89 88 88 88 90 89 90 88 88 89 91 96 97 96
27 SENGOTAVAN 85 79 75 77 80 78 78 78 78 78 77 80 80 80 80 80 76 78
28 BABU 94 86 87 88 90 88 88 89 90 88 90 88 90 90 90 89 91 91
29 KALPANA 78 70 71 78 80 78 77 77 78 80 77 77 78 77 76 77 76 76
30 ABDUL RAHEEM 87 80 83 84 85 84 87 87 88 86 88 88 89 84 85 85 86 84
31 VINODHINI 102 98 99 100 106 106 105 101 102 102 100 100 99 103 100 102 100 102
32 NIROSHA 98 90 92 93 90 90 87 81 87 95 96 92 93 93 94 95 96 95
33 RAJA 89 78 80 82 81 82 82 82 82 80 81 79 80 81 81 83 85 82
34 JAMUL RASHI 95 87 88 90 88 90 90 90 92 91 91 92 91 91 90 89 90 90
35 SAFEENA BEGUM 82 77 80 80 81 81 80 80 79 78 77 80 80 81 79 80 80 80
36 RAMANI 105 90 88 92 92 90 90 91 89 91 90 91 90 89 96 90 91 91
37 SELVI 86 80 85 88 87 87 87 87 88 88 87 88 89 88 87 85 86 89
38 JAFFER ALI 103 99 98 99 97 100 99 99 100 100 98 98 100 98 99 99 100 102
39 SHAJITHA 82 78 80 81 80 81 80 81 81 81 81 80 79 80 84 80 80 80
40 NITHYA 77 72 74 76 76 78 76 77 78 80 78 77 78 77 77 77 76 76
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
41 JOTHI 88 82 81 82 81 81 79 80 80 82 80 80 80 81 80 81 83 82
42 THAHIRA BEGUM 92 85 89 90 89 88 86 89 90 88 90 88 89 93 89 90 88 88
43 ANNAPURNI 103 94 95 96 95 101 100 100 100 101 99 100 99 102 100 106 100 100
44 PUSHPALATHA 82 75 80 81 83 81 80 81 81 81 81 80 79 80 81 80 80 80
45 CHINRASU 108 92 97 99 99 100 99 100 98 99 98 100 99 99 100 106 102 102
46 JAYASURYA 79 72 78 80 77 78 79 80 80 78 76 76 77 77 82 78 78 80
47 THAMEEM 96 90 88 90 88 90 90 89 89 90 91 92 92 91 90 89 90 90
48 INDHIRA 83 77 78 79 79 80 80 80 80 80 78 80 80 81 84 81 80 80
49 LOGANATHAN 105 93 91 97 98 98 99 98 98 100 99 99 99 98 100 98 99 100
50 AMBIKAI 86 79 76 78 77 77 78 77 78 80 79 79 78 79 80 80 80 80
51 SAFASUL 99 91 98 99 99 100 99 99 100 100 99 98 101 103 102 102 100 102
52 SHEIK DAMOOD 94 84 89 89 91 90 88 91 90 89 90 90 90 90 93 90 89 89
53 KUPPAM 84 76 75 81 80 80 80 79 79 80 80 81 81 80 81 85 80 80
54 MARY 98 92 92 92 91 93 93 93 93 94 94 92 91 90 92 94 91 90
55 SHANKAR 100 90 92 93 91 92 90 92 91 91 90 91 90 90 96 92 91 92
56 JAYAPREETHIKA 84 76 80 82 84 83 84 83 83 83 84 83 84 83 86 86 82 80
57 GOMATHI 82 77 79 78 79 80 80 80 80 79 79 80 80 84 80 80 80 80
58 MEENAKSHI 78 71 72 75 72 73 72 73 72 70 73 72 71 73 70 72 73 72
59 SAJIK AHMED 102 89 87 88 87 88 90 90 92 95 92 90 90 92 90 91 92 94
60 SUNDARI 88 82 81 82 83 82 81 82 82 86 80 81 82 82 81 82 82 82
BUPIVACAINE WITH NEOSTIGMINE
BUPIVACAINE
BUPIVACAINE WITH FENTANYL
MEAN ARTERIAL BLOOD PRESSURE
MEAN ARTERIAL BLOOD PRESSURE
MEAN ARTERIAL BLOOD PRESSURE
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
1 NAGAMMAL 14 16 12 12 12 12 13 12 15 12 12 20 18 15 13 14 16 14
2 DEVARAJ 12 14 13 12 12 12 13 11 12 10 12 12 14 14 13 14 14 14
3 RANGANATHAN 12 13 12 12 12 12 12 12 12 11 10 12 15 15 12 12 12 12
4 PACHYAMMAL 14 12 12 12 12 12 12 15 12 12 12 18 16 14 12 13 12 12
5 RAJESHWARI 12 15 12 12 12 12 12 12 12 10 10 12 12 14 15 14 12 12
6 PONGOTHAI 13 14 12 12 12 12 12 12 18 12 10 12 14 12 12 12 12 12
7 KAVERY 10 12 12 12 12 12 12 12 14 10 10 11 12 12 14 12 12 12
8 MALLIKA 14 12 12 12 12 12 12 12 12 12 10 11 12 10 14 15 13 14
9 SENTHAMARAI 12 12 12 12 12 12 12 12 12 11 14 10 12 15 16 14 14 14
10 PAZHANI 12 11 12 12 12 12 12 12 12 11 10 11 10 12 12 12 14 12
11 VICTORIA 14 12 12 12 12 12 12 12 14 10 12 14 13 12 14 14 14 12
12 DHANDAPANI 12 12 11 12 12 12 12 12 11 10 12 12 12 13 14 12 12 13
13 VIMALA 15 12 12 12 12 12 12 15 12 12 12 12 12 12 13 14 14 15
14 VEERAPANDI 10 12 12 12 12 12 11 12 14 10 11 12 12 12 12 12 13 14
15 GOWRI 13 13 12 12 12 12 12 15 14 11 10 12 15 12 12 12 12 12
16 KALAISELVI 14 12 12 12 12 12 12 12 14 11 10 14 14 12 12 14 12 14
17 MUNUSAMY 10 12 12 12 12 12 12 12 14 11 11 12 14 12 12 12 12 12
18 GANGAMMAL 12 12 12 12 12 12 12 12 14 11 12 12 12 14 15 12 12 12
19 GANGA 12 13 12 12 12 12 12 14 14 11 12 12 12 12 12 12 15 12
20 SARANYA 14 13 12 12 12 12 12 11 12 11 11 13 14 13 13 12 12 12
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
21 ILAMATHI 12 12 12 12 12 12 12 12 14 10 12 10 10 12 14 12 14 12
22 VANMATHY 12 12 11 12 12 12 12 12 11 10 12 12 12 12 14 12 12 13
23 LAKSHMI 12 12 12 12 12 12 12 15 13 12 12 10 12 12 13 14 12 13
24 AFRIN BANU 14 12 12 12 12 12 11 12 14 10 12 11 12 12 15 14 13 14
25 THAMARAI 13 13 12 12 12 12 12 15 14 11 10 12 12 12 14 14 15 14
26 SULOCHANA 14 12 12 12 12 12 12 12 14 11 10 12 14 12 12 14 12 14
27 SENGOTAVAN 10 12 12 12 12 12 12 12 12 11 11 12 12 12 12 12 12 12
28 BABU 12 12 12 12 12 12 12 12 14 11 10 10 12 12 15 12 12 12
29 KALPANA 12 13 12 12 12 12 12 14 14 11 12 12 12 14 14 12 15 14
30 ABDUL RAHEEM 14 13 12 12 12 12 12 11 12 11 11 12 14 13 13 12 12 14
31 VINODHINI 14 16 12 12 12 12 13 12 15 12 12 12 13 15 18 14 16 14
32 NIROSHA 12 14 13 12 12 12 13 11 12 10 12 12 14 14 13 14 14 14
33 RAJA 12 13 12 12 12 12 12 12 12 11 10 12 12 15 13 12 12 12
34 JAMUL RASHI 14 12 12 12 12 12 12 15 12 12 12 12 14 14 15 13 12 12
35 SAFEENA BEGUM 12 15 12 12 12 12 12 12 12 10 10 11 12 14 15 14 12 12
36 RAMANI 13 14 12 12 12 12 12 12 18 12 10 12 12 12 12 12 12 13
37 SELVI 10 12 12 12 12 12 12 12 14 12 10 11 12 12 14 12 12 12
38 JAFFER ALI 14 12 12 12 12 12 12 12 12 12 10 11 12 10 14 15 13 12
39 SHAJITHA 12 12 12 12 12 12 12 12 12 11 14 10 12 15 16 14 14 13
40 NITHYA 12 11 12 12 12 12 12 12 12 11 10 11 10 12 12 12 14 11
BUPIVACAINE WITH NEOSTIGMINE
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
41 JOTHI 12 13 12 12 12 12 12 14 14 11 12 12 12 18 12 12 15 12
42 THAHIRA BEGUM 13 13 12 12 11 12 12 11 12 11 11 13 14 13 13 12 12 12
43 ANNAPURNI 14 12 12 12 12 12 13 12 15 12 12 13 14 19 13 14 16 14
44 PUSHPALATHA 12 14 13 12 12 12 13 11 12 10 12 12 14 14 13 14 14 14
45 CHINRASU 10 13 12 12 12 12 12 12 12 11 10 12 12 15 12 12 12 12
46 JAYASURYA 13 14 12 12 12 12 12 12 18 12 10 12 13 12 12 12 12 13
47 THAMEEM 10 12 12 12 12 12 12 12 14 10 10 11 12 15 14 12 12 14
48 INDHIRA 14 12 12 12 12 12 12 12 12 12 10 11 11 14 14 15 13 12
49 LOGANATHAN 10 12 12 12 12 12 12 12 12 11 14 10 12 15 16 14 14 13
50 AMBIKAI 12 11 12 12 12 12 12 12 12 11 13 11 10 12 15 14 14 11
51 SAFASUL 14 12 12 12 12 12 12 12 14 10 12 14 13 12 14 14 14 12
52 SHEIK DAMOOD 12 12 11 12 12 12 12 12 11 10 12 12 12 13 14 12 12 13
53 KUPPAM 15 12 12 12 12 12 12 15 12 12 12 12 12 12 13 14 14 15
54 MARY 10 12 12 12 12 12 11 12 14 10 11 12 12 12 12 12 13 14
55 SHANKAR 10 13 12 12 12 12 12 15 14 11 10 12 15 12 12 12 12 12
56 JAYAPREETHIKA 12 12 12 12 12 12 12 15 12 12 12 12 16 14 12 13 12 12
57 GOMATHI 12 15 12 12 12 12 12 12 12 10 10 12 12 14 15 14 12 12
58 MEENAKSHI 13 14 12 12 12 12 12 12 18 12 10 12 14 12 12 12 12 13
59 SAJIK AHMED 10 12 12 12 12 12 12 12 14 10 10 11 12 12 14 12 12 12
60 SUNDARI 14 12 12 12 12 12 12 12 12 12 10 11 12 10 14 15 13 12
BUPIVACAINE
BUPIVACAINE WITH FENTANYL
RESPIRATORY RATE
RESPIRATORY RATE
RESPIRATORY RATE
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
1 NAGAMMAL 99 100 100 100 100 100 100 99 100 100 100 100 98 100 100 100 100 100 0
2 DEVARAJ 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 0
3 RANGANATHAN 100 100 100 100 100 100 100 100 100 100 100 99 100 99 100 100 100 100 0
4 PACHYAMMAL 99 100 100 100 100 100 100 100 100 100 100 98 99 100 100 100 100 100 0
5 RAJESHWARI 98 100 100 100 99 100 100 100 100 100 100 97 100 99 99 99 100 99 0
6 PONGOTHAI 100 100 100 100 100 100 100 100 100 100 100 98 100 99 100 100 100 100 0
7 KAVERY 99 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 100 0
8 MALLIKA 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
9 SENTHAMARAI 100 100 100 99 100 100 100 100 100 100 100 99 100 100 100 100 100 100 0
10 PAZHANI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
11 VICTORIA 100 100 100 100 99 100 100 100 100 100 100 97 99 99 100 100 100 100 0
12 DHANDAPANI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
13 VIMALA 100 100 100 100 100 100 100 99 100 100 100 99 100 100 100 100 100 100 0
14 VEERAPANDI 100 100 99 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 0
15 GOWRI 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 0
16 KALAISELVI 100 100 100 100 100 100 100 100 100 100 100 99 99 100 100 100 100 100 0
17 MUNUSAMY 99 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 0
18 GANGAMMAL 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 0
19 GANGA 99 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 100 0
20 SARANYA 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
BUPIVACAINE WITH FENTANYL
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
21 ILAMATHI 100 100 100 100 100 100 100 99 100 100 100 100 100 100 100 100 100 100 1
22 VANMATHY 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1
23 LAKSHMI 99 100 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 1
24 AFRIN BANU 99 100 100 100 100 100 100 100 99 100 100 99 100 98 100 100 99 100 0
25 THAMARAI 100 100 99 100 100 100 100 100 100 100 100 99 100 100 99 99 100 99 1
26 SULOCHANA 100 100 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 1
27 SENGOTAVAN 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
28 BABU 100 100 100 100 100 100 100 100 100 100 100 100 99 99 100 100 100 100 1
29 KALPANA 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1
30 ABDUL RAHEEM 100 100 100 100 100 99 100 100 100 100 100 100 100 100 100 100 99 100 0
31 VINODHINI 100 100 100 100 99 100 100 100 100 100 100 100 99 100 100 100 100 100 0
32 NIROSHA 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 0
33 RAJA 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1
34 JAMUL RASHI 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1
35 SAFEENA BEGUM 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 99 0
36 RAMANI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 0
37 SELVI 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
38 JAFFER ALI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1
39 SHAJITHA 99 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 1
40 NITHYA 100 100 100 100 100 99 100 100 100 100 100 100 100 100 100 100 100 99 1
BUPIVACAINE WITH NEOSTIGMINE
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
41 JOTHI 100 100 100 100 100 100 100 100 100 100 100 100 98 99 100 100 100 100 0
42 THAHIRA BEGUM 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 100 100 100 0
43 ANNAPURNI 100 100 100 100 99 100 100 100 100 100 100 100 100 100 100 100 100 100 0
44 PUSHPALATHA 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 100 0
45 CHINRASU 100 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 0
46 JAYASURYA 100 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 0
47 THAMEEM 99 100 100 100 100 100 100 100 99 100 100 100 100 100 100 99 100 100 0
48 INDHIRA 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
49 LOGANATHAN 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
50 AMBIKAI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
51 SAFASUL 100 100 99 100 100 100 100 100 100 99 100 100 99 100 100 100 100 99 1
52 SHEIK DAMOOD 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
53 KUPPAM 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
54 MARY 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
55 SHANKAR 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
56 JAYAPREETHIKA 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 100 100 99 0
57 GOMATHI 100 100 100 100 100 99 100 100 100 100 100 100 100 99 100 100 100 100 0
58 MEENAKSHI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
59 SAJIK AHMED 99 100 100 100 100 100 100 100 99 99 100 100 100 100 100 100 100 100 0
60 SUNDARI 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0
BUPIVACAINE
OXYGEN SATURATION
OXYGEN SATURATION
OXYGEN SATURATION
NAUSEA / VOMITING
NAUSEA / VOMITING
NAUSEA / VOMITING
BUPIVACAINE
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN PRURITUS
1 NAGAMMAL 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
2 DEVARAJ 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
3 RANGANATHAN 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
4 PACHYAMMAL 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
5 RAJESHWARI 2 - - - - - - - - 1 2 2 2 2 2 2 2 2 0
6 PONGOTHAI 2 - - - - - - - 2 2 2 2 2 2 2 2 2 2 0
7 KAVERY 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
8 MALLIKA 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
9 SENTHAMARAI 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
10 PAZHANI 2 - - - - - - - 1 2 2 2 2 2 2 2 2 2 0
11 VICTORIA 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
12 DHANDAPANI 2 - - - - - - - - 1 2 2 2 2 2 2 2 2 0
13 VIMALA 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
14 VEERAPANDI 2 - - - - - - - - 1 2 2 2 2 2 2 2 2 0
15 GOWRI 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
16 KALAISELVI 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
17 MUNUSAMY 2 - - - - - - - 2 2 2 2 2 2 2 2 2 2 0
18 GANGAMMAL 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
19 GANGA 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
20 SARANYA 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN PRURITUS
21 ILAMATHI 2 - - - - - - - - 3 4 4 3 3 2 2 2 2 1
22 VANMATHY 2 - - - - - - - - 2 3 4 3 3 2 2 2 2 1
23 LAKSHMI 2 - - - - - - - - 2 3 3 3 2 2 2 2 2 1
24 AFRIN BANU 2 - - - - - - - - 2 2 3 3 2 2 2 2 2 0
25 THAMARAI 2 - - - - - - - - 3 3 4 3 2 2 2 2 2 1
26 SULOCHANA 2 - - - - - - - 3 3 4 4 3 3 3 2 2 2 1
27 SENGOTAVAN 2 - - - - - - - - 3 3 3 3 2 2 2 2 2 0
28 BABU 2 - - - - - - - - 2 2 3 3 2 2 2 2 2 0
29 KALPANA 2 - - - - - - - - 2 4 4 4 3 2 2 2 2 1
30 ABDUL RAHEEM 2 - - - - - - - - 2 3 3 3 3 2 2 2 2 0
31 VINODHINI 2 - - - - - - - - 3 4 4 3 3 3 2 2 2 1
32 NIROSHA 2 - - - - - - - - 3 3 3 3 3 2 2 2 2 1
33 RAJA 2 - - - - - - - 4 2 2 3 3 2 2 2 2 2 0
34 JAMUL RASHI 2 - - - - - - - - 2 3 3 3 2 2 2 2 2 1
35 SAFEENA BEGUM 2 - - - - - - - 4 3 3 4 3 3 3 2 2 2 0
36 RAMANI 2 - - - - - - - - 2 3 3 3 3 3 2 2 2 1
37 SELVI 2 - - - - - - - - 4 4 4 4 3 3 2 2 2 1
38 JAFFER ALI 2 - - - - - - - - 2 3 3 3 3 3 2 2 2 0
39 SHAJITHA 2 - - - - - - - - 3 3 3 3 2 2 2 2 2 0
40 NITHYA 2 - - - - - - - - 4 4 4 3 3 3 2 2 2 1
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN PRURITUS
41 JOTHI 2 - - - - - - - 2 2 2 2 2 2 2 2 2 2 0
42 THAHIRA BEGUM 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
43 ANNAPURNI 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
44 PUSHPALATHA 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
45 CHINRASU 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
46 JAYASURYA 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
47 THAMEEM 2 - - - - - - - - 3 2 2 2 2 2 2 2 2 0
48 INDHIRA 2 - - - - - - - 2 2 2 2 2 2 2 2 2 2 0
49 LOGANATHAN 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
50 AMBIKAI 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
51 SAFASUL 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
52 SHEIK DAMOOD 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
53 KUPPAM 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
54 MARY 2 - - - - - - - 2 2 2 2 2 2 2 2 2 2 0
55 SHANKAR 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
56 JAYAPREETHIKA 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
57 GOMATHI 2 - - - - - - - - 3 2 2 2 2 2 2 2 2 0
58 MEENAKSHI 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
59 SAJIK AHMED 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
60 SUNDARI 2 - - - - - - - - 2 2 2 2 2 2 2 2 2 0
BUPIVACAINE WITH NEOSTIGMINE
BUPIVACAINE WITH FENTANYL
RAMSAY SEDATION SCORE
RAMSAY SEDATION SCORE
RAMSAY SEDATION SCORE
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
TIME FOR FIRST 
RESCUE  ANALGESIA
1 NAGAMMAL - - - - - - - - - 0 1 9 5 4 3 5 5 4 104 MINS
2 DEVARAJ - - - - - - - - 0 1 2 8 4 4 5 4 5 5 115 MINS
3 RANGANATHAN - - - - - - - - 0 0 10 6 5 5 5 6 5 6 91 MINS
4 PACHYAMMAL - - - - - - - - 0 1 9 6 5 4 5 4 5 4 101 MINS
5 RAJESHWARI - - - - - - - - - 0 1 9 8 6 6 6 5 5 104 MINS
6 PONGOTHAI - - - - - - - - - 1 0 9 8 6 6 5 6 5 110 MINS
7 KAVERY - - - - - - - - - 1 0 10 7 5 6 5 6 5 107 MINS
8 MALLIKA - - - - - - - - - 0 0 8 5 4 4 3 4 4 100 MINS
9 SENTHAMARAI - - - - - - - - 0 0 9 5 4 4 4 5 4 4 113 MINS
10 PAZHANI - - - - - - - - - 1 0 10 8 7 6 5 6 5 103 MINS
11 VICTORIA - - - - - - - - - 0 1 9 5 4 3 3 3 3 109 MINS
12 DHANDAPANI - - - - - - - - - 1 0 9 3 3 4 3 3 3 114 MINS
13 VIMALA - - - - - - - - - 1 0 10 7 5 6 5 6 5 102 MINS
14 VEERAPANDI - - - - - - - - - 0 0 8 5 4 4 3 3 3 114 MINS
15 GOWRI - - - - - - - - - 0 9 5 4 4 4 5 4 4 105 MINS
16 KALAISELVI - - - - - - - - - 1 0 9 8 6 7 6 6 6 107 MINS
17 MUNUSAMY - - - - - - - - 0 0 9 4 4 5 3 3 4 3 104 MINS
18 GANGAMMAL - - - - - - - - - 1 2 8 4 4 5 4 5 5 111 MINS
19 GANGA - - - - - - - - - 0 9 6 5 5 5 6 5 6 98 MINS
20 SARANYA - - - - - - - - - 1 9 9 6 6 5 6 6 6 104 MINS
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
TIME FOR FIRST 
RESCUE  ANALGESIA
21 ILAMATHI - - - - - - - - - 0 1 0 0 0 9 5 4 4 277 MINS
22 VANMATHY - - - - - - - - 0 0 0 1 1 1 8 4 4 4 301 MINS
23 LAKSHMI - - - - - - - - - 0 0 1 1 1 3 9 5 4 285 MINS
24 AFRIN BANU - - - - - - - - 0 0 0 0 0 1 8 3 3 3 297 MINS
25 THAMARAI - - - - - - - - - 0 0 1 1 2 2 9 4 3 271 MINS
26 SULOCHANA - - - - - - - - - 0 0 0 1 1 2 6 3 2 287 MINS
27 SENGOTAVAN - - - - - - - - - 1 0 0 0 3 9 6 6 5 281 MINS
28 BABU - - - - - - - - 0 0 0 0 0 1 8 3 3 2 299 MINS
29 KALPANA - - - - - - - - - - 0 1 2 2 2 1 6 7 278 MINS
30 ABDUL RAHEEM - - - - - - - - - 1 0 0 0 0 6 5 4 4 297 MINS
31 VINODHINI - - - - - - - - - 0 0 0 1 2 8 5 3 5 261 MINS
32 NIROSHA - - - - - - - - - 1 0 2 1 0 10 4 4 3 289 MINS
33 RAJA - - - - - - - - - 0 0 0 0 0 0 5 3 2 312 MINS
34 JAMUL RASHI - - - - - - - - 0 0 0 0 0 1 6 4 3 2 306 MINS
35 SAFEENA BEGUM - - - - - - - - - 0 1 0 1 1 9 4 3 4 286 MINS
36 RAMANI - - - - - - - - - 0 1 1 1 1 7 5 4 4 276 MINS
37 SELVI - - - - - - - - 1 2 2 3 2 9 7 6 5 5 303 MINS
38 JAFFER ALI - - - - - - - - 0 0 0 0 0 1 7 3 2 2 300 MINS
39 SHAJITHA - - - - - - - - - 0 0 1 2 1 8 5 4 3 293 MINS
40 NITHYA - - - - - - - - - 0 0 1 1 3 7 4 5 4 288 MINS
SL. NO NAME BASELINE  15MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 180 MIN 240 MIN 300 MIN 360 MIN 420 MIN 480 MIN 540 MIN 600 MIN 660 MIN 720 MIN
TIME FOR  FIRST 
RESCUE  ANALGESIA
41 JOTHI - - - - - - - - - 0 1 2 2 1 5 6 3 5 257 MINS
42 THAHIRA BEGUM - - - - - - - - - 1 0 0 1 1 9 4 3 3 276 MINS
43 ANNAPURNI - - - - - - - - - 0 0 1 2 1 8 4 3 3 251 MINS
44 PUSHPALATHA - - - - - - - - 0 0 0 1 0 6 3 3 4 2 256 MINS
45 CHINRASU - - - - - - - - 0 0 1 1 0 7 4 4 3 4 251 MINS
46 JAYASURYA - - - - - - - - 0 1 0 0 1 2 6 5 4 5 283MINS
47 THAMEEM - - - - - - - - - 1 0 2 1 0 9 7 5 5 249 MINS
48 INDHIRA - - - - - - - - - - 1 1 2 2 10 7 5 6 236 MINS
49 LOGANATHAN - - - - - - - - 0 0 0 1 0 7 4 3 3 3 264 MINS
50 AMBIKAI - - - - - - - - - 0 1 1 2 8 4 5 4 3 267 MINS
51 SAFASUL - - - - - - - - - 0 0 1 1 7 6 5 3 4 247 MINS
52 SHEIK DAMOOD - - - - - - - - 0 0 0 0 1 1 7 4 3 4 275 MINS
53 KUPPAM - - - - - - - - - 0 1 1 2 2 9 6 5 4 281 MINS
54 MARY - - - - - - - - - 0 0 1 1 1 7 5 4 5 266 MINS
55 SHANKAR - - - - - - - - - 2 2 3 2 9 7 6 5 5 241 MINS
56 JAYAPREETHIKA - - - - - - - - 0 1 1 2 2 3 9 6 5 5 247 MINS
57 GOMATHI - - - - - - - - - 0 0 1 0 1 8 4 5 4 281 MINS
58 MEENAKSHI - - - - - - - - - 0 0 2 1 2 7 3 2 3 283 MINS
59 SAJIK AHMED - - - - - - - - 0 0 0 1 2 8 4 3 4 4 269 MINS
60 SUNDARI - - - - - - - - - 0 1 1 2 6 5 4 5 4 255MINS
VISUAL ANALOGUE SCALE
VISUAL ANALOGUE SCALE
VISUAL ANALOGUE SCALE
BUPIVACAINE
BUPIVACAINE WITH FENTANYL
BUPIVACAINE WITH NEOSTIGMINE
